Cross-omics integration shows cortex-wide synaptic dysfunction at later stages of Alzheimer disease

Abdallah M. Eteleeb[1,2,3], Brenna C. Novotny[1], Carolina Soriano Tarraga[1], Christopher Sohn[1], Eliza Dhungel[4], Logan Brase[1], Aasritha Nallapu[1], Jared Buss[1], Fabiana Farias[1,2], Kristy Bergmann[1,2], Joanne Norton[1,2], Jen Gentsch[1,2], Fengxian Wang[1,2], Albert A. Davis[5,7], John C. Morris[3,5,7], Celeste M. Karch[1,2,3,7], Richard J. Perrin[3,6,7], Bruno A. Benitez[8], Oscar Harari[1,3,7#].

[1]Department of Psychiatry, Washington University, Saint Louis, St. Louis, MO, USA

[2]NeuroGenomics and Informatics Center, Washington University, St. Louis, MO, USA

[3]The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University, St. Louis, MO, USA

[4]Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA

[5]Department of Neurology, Washington University, St. Louis, MO, USA

[6]Department of Pathology and Immunology, Washington University, St. Louis, MO, USA

[7]Hope Center for Neurological Disorders, Washington University, St. Louis, MO, USA

[8]Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA

#To whom the correspondence should be addressed:

Oscar Harari, PhD

Department of Psychiatry

Washington University School of Medicine

4444 Forest Park Ave., Saint Louis, Missouri, 63110

E-mail: harario@wustl.edu

Abstract

Clinical and molecular heterogeneity of Alzheimer disease (AD) is increasingly recognized as a major factor impacting the diagnosis, the design of therapeutic interventions and clinical trials, and therefore possibly delaying the development of effective treatments for AD. We sought to determine whether cross-omics integration reveals molecular profiles of AD with clinical and biological relevance. By leveraging cross-omics approaches, we integrated high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles from AD and control cases from multiple cortical regions and cohorts. We identified four distinct molecular profiles in which a specific profile was associated with significantly higher Clinical Dementia Rating (CDR) at death, shorter survival after onset, more severe neurodegeneration and astrogliosis, and decreased

levels of metabolomic profiles. Its molecular signatures show significant dysregulation of synaptic

genes indicating neuron/synapse losses and dysfunction at later stages of AD, and present in

multiple cortical regions. Among other molecules, we found that the expression of alpha-synuclein

(*SNCA*) and *SNAP25* were downregulated in this profile. Overall, our results suggest that AD has

a more prominent synaptic loss and dysfunction associated with worse cognition. These novel

molecular findings open the possibility for new biomarkers for the molecular staging of AD and

potential therapeutic targets to ameliorate cognitive decline and AD progression.

Main

Alzheimer disease (AD) is a neurodegenerative disorder pathologically characterized by amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), neuroinflammation, and synaptic and neuronal loss. AD is the most common cause of dementia among the elderly, currently affecting approximately 6.2 million individuals of age 65 and older in the United States and 50 million worldwide[1]. However, AD shows a large genetic, clinical, and pathological heterogeneity. Similar to the variability of patterns and rates at which amyloid deposition, tauopathy, and neurodegeneration are observed among the affected population[2–4], participants with variable degrees of cognitive impairment at the time of death can exhibit very similar AD associated neuropathology. In addition, AD pathology hallmarks are commonly accompanied by variable burdens of one or more other additional neurodegenerative pathologic features, including cerebrovascular lesions, Lewy body pathology, and TDP-43 proteinopathy[3]. Concordant with these observations, growing evidence suggests that molecular profiles also differ substantially within AD[5,6]. This multifaceted heterogeneity suggests that multiple biological pathways are involved in AD – presenting a major challenge for the development of therapeutic interventions and companion diagnostics. However, the heterogeneity of AD has not been fully considered in the design of therapeutic interventions and clinical trials, possibly because of a detailed map of the AD molecular heterogeneity is still missing. Characterizing this heterogeneity on a biological level – by identifying specific changes in synapse/neuronal population, demyelination, glial activation, for instance – may provide critical insights to develop new peripheral biomarkers, companion diagnostics, and therapeutic interventions, tailor the design of clinical trials, and bring closer precision medicine for AD.

In recent years, multiple clinical and pathological AD subtypes have been identified based on distinct spatiotemporal trajectories of tau pathology, brain atrophy, postmortem brain transcriptomics profiles, and cerebrospinal fluid proteomics. Differences in characteristics associated with these subtypes including, age at onset, sex, APOE ℰ4 carrier status, cognitive status, disease duration, and cerebrospinal fluid (CSF) biomarker levels, were previously reported[2,3,5–11]. Prior research efforts have leveraged molecular profiles and biomarkers to characterize the AD population into subgroups, and have provided information on AD progression, that in turn could be used in clinical trials. However, the influence that such AD profiles may have on cognitive decline remains poorly understood and under-studied, representing a barrier to using this information effectively in clinical trials of potential disease-modifying therapies.

Previous studies have proposed multiple AD subtypes examining clinical, neuropathological, and
molecular features[7]. Recently, distinct spatiotemporal tau deposition trajectories have been
identified using tau PET imaging[2], which suggest significant differences between sex, APOE e4,
and age. In parallel, three AD subtypes associated with multiple dysregulated pathways, such as
susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic
signaling, immune activity, mitochondria organization, and myelination using a system biology
approach to study transcriptomics from multiple cortical regions[5]. Despite the substantial effort in
identifying molecular subtypes of AD described in this study, broader conclusions are limited by
its nature as a single-omics analyses typically captures changes in a single component of the
biological cascade.
95
Comprehensive studies that aggregate multiple modalities of omics (cross-omics) have proven to
be a powerful way to identify molecular subtypes for complex human diseases including cancer[12–]
[17]. Omics layers describe the biological system at different biomolecular levels[18], allowing more
comprehensive segregation of AD biology into molecular profiles that the partial analyses of any
individual modality might miss. Cross-omics approaches can reveal not only how complex
biomolecular profiles change with the disease, but also the relationships and correlations between
distinct classes of biological molecules. Their potential for studying neurodegeneration has been
previously described[19–28]. However, only recently deep molecular characterization of multiple
cortical regions from diverse brain banks and cohorts has only recently been generated[5,6], which
now enables a more detailed and comprehensive examination of cross-omics data in AD.
106
In the current study, we leveraged machine learning, digital deconvolution, and traditional
statistical approaches to integrate and analyze multiple high-throughput *omics* from different
cortical regions and cohorts. Our cross-omics data integration approach identified distinct
molecular profiles of AD associated with cognitive function and clinical attributes. Our results
highlight that molecular heterogeneity is a common characteristic in AD brains and by virtue of
molecular stratification, cross-omics approaches reveal multiple molecular pathways associated
with AD progression. Overall, these results provide a foundation for implementing precision
medicine approaches for AD.
115

Results

Study design

We leveraged high-throughput transcriptomic, proteomic, metabolomic and lipidomic data from

the parietal cortex of participants with neuropath-confirmed AD from the Knight Alzheimer Disease

Research Center (Knight ADRC) for our discovery cohort (see Methods, **Fig. 1** and **Table 1**).

Omics data were generated using next-generation sequencing, SomaScan, and Metabolon

Precision Metabolomics platforms for transcriptomic (60,0754 transcripts)[29–31], proteomic (1,092

proteins)[32], and metabolomic (627 metabolites)[33] respectively (see Methods). Preprocessing,

quality control (QC), and feature selection were performed on each omics data type, and only

samples that passed the QC criteria in the three omics modalities were retained, resulting in 278

samples (255 AD and 23 control). We employed a Bayesian integrative clustering method named

iClusterBayes[34] to integrate AD multi-omics data (see Methods) and identify molecular profiles of

AD. Control cases were later integrated for comparative analyses.

To investigate the biological relevance of the AD molecular profiles, we performed multiple

association analyses including association with clinical and neuropathological attributes (e.g. sex,

age of death, age at onset, post-mortem interval, CDR, Braak, etc.), survival, and differential

expression analyses to characterize AD molecular profiles. We leveraged digital deconvolutions

approaches to infer the cellular population structure using bulk RNA-seq data[31], and tested for

association of these profiles with cell-type abundances. We have also integrated single-nuclei

RNA-seq data (snRNA-seq) from the parietal cortex from 67 Knight ADRC participants to

determine the specific cell-type effects.

For replication, we leveraged transcriptomics (RNA-seq) and proteomics (tandem mass tag;TMT)

from 116 brains (93 AD and 23 control, **Table 1**) extracted from the parahippocampal gyrus

(BM36) from The Mount Sinai Brain Bank (MSBB) study[35] as well as transcriptomics data from

237 brains (144 AD and 93 control, **Table 1**) from the dorsolateral prefrontal cortex (DLPFC) from

The Religious Orders Study and Memory and Aging Project (ROSMAP) cohort[36] accessed

through the AMP-AD Synapse portal. Preprocessing, QC, and feature selection were performed

similar to the discovery datasets.

Identification of distinct molecular profiles of Alzheimer disease

We sought to investigate how multiple *omic* modalities capture optimally the molecular

heterogeneity in AD, without any additional conditioning on additional neuropathological or clinical

data. We used Bayesian information criteria (BIC) to evaluate clustering solutions between 2 and

10 clusters and identified four clusters (Knight-Clusters, **Fig. 2a**) which maximized compactness

(intra-cluster similarity). Among the four clusters, we observed that the molecular profiles of Cluster4 (named Knight-C4 hereafter, n=42) exhibited more pronounced dysregulation for many molecules compared to AD participants from other clusters. For instance, the transcriptomic profiles of the top 75% quantile genes show significant dysregulation signatures associated with Knight-C4 (**Fig. 2b**).

Cross-omics analyses identified a molecular profile of AD brains associated with worse cognitive function and molecular attributes

We initially evaluated whether the alternative molecular profiles were associated with genetic risk factors, neuropathological status, or clinical and demographic variables. We found that AD cases in Knight-C4 showed more severe cognitive decline, measured by significantly higher Clinical Dementia Rating (CDR) scores at death (p=5.24x10^{-3}; **Fig. 2c**), shorter survival time following disease onset (8 months shorter, **Fig. 2d**, p=4.2 x10^{-3}, HR=1.6) and younger age at death (**Fig. 2d**, p=4.2 x10^{-3}, HR=1.7) compared to donors in Knight-C1-3. However, the Knight-C4 cluster was not associated with either AD polygenic risk score (**Supplementary Fig. 2**) or APOE Ɛ4 allele carrier status (**Supplementary Fig. 3a**). We did not detect any significant association between Knight-C4 and either Braak neurofibrillary tangle stage or amyloid-β plaque score (**Supplementary Fig. 3b,c**). It is worth mentioning that these annotations are not complete for all the brains, restraining the statistical power.

Next, we leveraged digital deconvolution methods to infer the cellular population structure from bulk RNA-seq[31] (see Methods). We identified that the parietal cortices from donors in Knight-C4 show significantly higher astrocyte and lower neuronal proportions (**Fig. 2e and Supplementary Table 1**). We then evaluated whether a metabolomic profile that we previously reported associated with AD duration[33] would reveal additional molecular differences among the clusters. Lower values of this profile (or *eigenmetabolite*) were associated with a longer disease duration driven by earlier onset[33]. We found that brains in Knight-C2 and Knight-C4 exhibited significantly lower eigenmetabolite scores (**Fig. 2f**) using ordinal logistic regression (p=6.0x10^{-03}).

Altogether, these results show the feasibility of our approach in extracting novel insights from AD subpopulations by identifying a late-stage AD profiles associated with more neuronal loss and astrogliosis that caused more alterations in different molecular processes.

The AD molecular profile associated with worse cognition is represented consistently across multiple cortical regions

We sought to investigate whether the molecular profile associated with worse cognitive outcomes

was specific to the parietal cortex or also present in additional cortical regions affected at distinct

stages of AD. Our analyses of the transcriptomics and proteomics from AD parahippocampal

gyrus (BM36) from the MSBB study[35] (**Table 1**) identified two distinct molecular profiles (**Fig. 3a**).

We identified that brains in Cluster1 (MSBB-C1) recapitulate the transcriptomic signatures we had

previously identified in Knight-C4. We also ascertained the extent of overlap between the

molecules dysregulated in Knight-C4 (**Supplementary Table 2**) and MSBB-C1 (**Supplementary**

Table 3) and determined a coincident profile of dysregulated genes (**Supplementary Fig. 4a**, p

< 2.2 x10^{-16} hypergeometric test, **Supplementary Table 4**). Furthermore, these donors in MSBB-

C1 also exhibited more severe dementia at expiration, shown by a significantly higher CDR scores

(p=1.5x10^{-3}, **Fig. 3b**), and estimated higher and lower proportions of astrocytes and neurons,

respectively (p=5.5x10^{-07} and 3.2x10^{-09} respectively; **Fig. 3c**, **Supplementary Table 1**) compared

to other AD cases in MSBB. Furthermore, MSBB-C1 was associated with higher Braak tau scores

(p=3.9x10^{-03}, **Supplementary Fig. 5a**). Although not significant (p=8.0x10^{-02}), these donors show

a trend suggesting earlier age of death (**Supplementary Fig. 5b**). In contrast, we did not identify

a significant overlap of dysregulated proteins between regions (p > 0.05, **Supplementary Fig.**

4b).

Furthermore, we leveraged RNA-seq generated from MSBB donors in additional cortical regions

and identified that the distinguishing molecular profile of MSBB-C1 is consistently present in

multiple cortical regions including frontal cortex (BM10), superior temporal gyrus (BM22), and

inferior frontal gyrus (BM44) (**Supplementary Fig. 5c**).

Similarly, our analyses of the RNA-seq from the dorsolateral prefrontal cortex (DLPFC) from the

ROSMAP cohort[36] identified subset of AD donors (**Fig. 3d**). Brains in Cluster1 (ROSMAP-C1)

recapitulated the transcriptomic profiles of Knight-C4 (p < 2.2 x10^{-16} hypergeometric test;

Supplementary Fig. 4c and Supplementary Table 4 and 5). Donors from ROSMAP-C1 showed

evidence of greater cognitive impairment and increased neuropathological AD scores, indicated

by significantly lower Mini-Mental State Examination scores (MMSE; p=4.4x10^{-02}; **Fig. 3e**), higher

tau tangle densities (p=1.3x10^{-02}) and neurofibrillary tangle burdens (PHF tau tangles, p=2.1x10^{-}

^{02}; **Supplementary Fig. 6a,b**). Although not significant (p > 0.05), ROSMAP-C1 showed a trend

to higher plaque densities—Global burden of AD pathology (**Supplementary Fig. 6c**, see

Methods and Bennett *et al.*,2012[36] for details on how these neuropathological variables are

identified). Cell proportions from deconvolution analysis (**Supplementary Table 1**) also showed

that ROSMAP-C1 has significantly higher astrocyte (p=3.1x10^{-08}) and lower neuron (p=9.7x10^{-14})

proportions (**Fig. 3f**).

Altogether, these results indicate that cellular and molecular profiles of AD cases with worse

cognitive status are similar across multiple cortical regions, usually affected at different stages of

AD pathology.

The parietal cortex of subjects with worse cognitive function exhibited a remarkable
molecular dysregulation

Differential expression (DE) analyses (see Methods, **Supplementary Tables 2,6,7**) showed that

Knight-C4 has a ~10-fold increase in the number of significantly differentially expressed genes

(DEGs) compared to other AD participants (**Table 2** and **Supplementary Fig. 7a**); furthermore,

90% of the 4,661 DEGs were unique to participants in the Knight-C4. (**Table 2** and **Fig. 4a-left**

panel). Similarly, we observed an increased number of proteins and metabolites (**Table 2** and

Supplementary Fig. 7b,c) with significant abundance levels in Knight-C4. However, we

determined that Knight-C2 has the largest number of dysregulated proteins. We identified 24

(34%), 232 (51%), and 250 (52%) significant proteins unique to Knight-C1, 2, and 4, respectively

(**Fig. 4b-left panel** and **Table 2**). We did not detect significant proteins dysregulated uniquely in

Knight-C3.

Knight-C4 was associated with cluster-specific significantly different metabolic reading levels (90

hits; **Table 2** and **Supplementary Fig. 7c**) while only one hit was detected in Knight-C2. Out of

the 90 hits, 80 (90%) significant metabolites were also significantly different between Knight-C4

and other AD cases. These results suggest that cross-omics analyses capture molecular

heterogeneity among AD cases that are otherwise missed in non-clustered *omics* specific

approaches.

To quantify the benefits provided by this cross-omics study that clusters AD brain donors using

multi-omics profiles, we performed DE analyses comparing all AD cases combined (un-clustered)

to control brains. Then, we determined the percentage of significant features detected in each

cluster that are not captured by un-clustered analyses (**Table 2**, **Fig. 4a-c-right panel**). We

observed that Knight-C4 exhibited the highest percentage of missed hits with 92%, 98%, and

100% for transcriptomics, proteomics, and metabolomics respectively (**Fig. 4a-c-right panel**).

Notably, a high percentage of hits was also observed with Knight-C2 in proteomics (98%). On the

other hand, un-clustered analyses identified a small percentage of significant features that are

not captured by clustered analyses. For instance, only 5% and 0.5% of un-clustered significant

hits for transcriptomics and proteomics, respectively were not captured by Knight-C4. No un-
clustered significant metabolites were missed by Knight-C4.

258
To further characterize distinct profiles of AD brains, we performed DE analyses to compare AD
brains in each cluster to brains in other clusters (**Supplementary Tables 2,6,7**). Knight-C4
showed the highest percentage of significant hits compared to other AD brains (**Fig. 4d** and **Table
3**). This significant difference was observed in transcriptomics with 6,822 significant hits compared
to 678, 22, and 1 for Knight-C1-3 (**Fig. 4d-outer track** and **Table** 3). Similarly, this difference was
observed in metabolites with 228 significant hits in Knight-C4 compared to 105, 0, and 0 for
Knight-C1-3 respectively (**Fig. 4d-inner track** and **Table 3**). No significant differences in the
number of hits were observed between the four clusters in proteomics with all clusters showed
relatively similar detections (**Fig. 4d-middle track** and **Table 3**). We also verified that none of the
omics dominate this solution, each of them capturing molecular heterogeneity among AD brains
that are not necessarily detected by other *omics* modalities.

270
271   In summary, these results show that molecular profiles of AD are heterogeneous, and cross-omics
272   integration approach can better identify the substantial differences within AD brains.

273
**The AD molecular profile associated with worse cognitive function is significantly enriched
in dysregulated synaptic genes and is associated with AD-related pathways**
We performed pathway analyses to characterize the brains with worse cognitive function. We
found that the hits in Knight-C4 are significantly enriched in dysregulated synaptic genes (**Fig.
4e,f**, **Supplementary Table 8**) using the annotation from The SynGO consortium[37] (p=1.0x10^{-15}
and p=4.8x10^{-45} for Knight-C4 vs Control and Knight-C4 vs Knight-C1-3 sets respectively) and
curated list from Fei *et al.,* 2018[38] (p=2.3x10^{-07} and p=1.1x10^{-21} for Knight-C4 vs Control and
Knight-C4 vs Knight-C1-3 sets respectively). Coincidently, molecular data from the MSBB and
ROSMAP studies replicated these results, as MSBB-C1 and ROSMAP-C1 were significantly
enriched in synaptic genes (**Supplementary Fig. 8a,b and Supplementary Table 8**). These
results suggest that synaptic and neuronal loss occurs at later stages of AD.

285
In addition, the pathway analyses of Knight-C4 identified multiple AD-related pathways (**Fig.
4g,h**). KEGG pathways identified intracellular trafficking and signaling pathways (**Fig. 4g**)
including Endocytosis (p=6.5x10^{-04}), Phagosome (p=1.2x10^{-06}), and mTOR signaling pathway
(p=3.3x10^{-02}), all of which were shown to play major roles in the pathological processes of AD[39–
41]. KEGG pathways also identified lysosomes (p=4.7x10^{-02}, **Fig. 4g**), a critical component within

cells. Growing evidence has shown that the dysfunction of lysosomes plays a major role in
pathogenesis of multiple neurodegenerative diseases including the progression of AD[42–46].
Another significant example associated with Knight-C4 was Autophagy (p=1.6x10[-02], **Fig. 4g**), a
pathway associated with several neurodegenerative disorders including AD[47–50]. For instance, the
dysfunction of autophagy was shown to be linked to the accumulation of misfolded protein
aggregates[51]. KEGG pathways results also show that the downregulation of Knight-C4, compared
to other AD cases, was associated with pathways related to multiple neurodegenerative diseases
(**Fig. 4g**), including AD (p=2.5x10[-14]), Huntington disease (p=3.3x10[-14]), and PD (p=2.1x10[-12])
suggesting that neuronal/synaptic loss and gliosis are common characteristics of most
neurodegenerative diseases at late-stages. These analyses also identified synaptic pathways,
including dopaminergic synapse (p=7.0x10[-03]) and glutamatergic synapse (p=1.0x10[-02]) (**Fig. 4g**).
Furthermore, GO biological process analyses identified significant neuronal differentiation
(p=1.8x10[-02]) and development (p=5.7x10[-03]) associated with Knight-C4 (**Fig. 4h**)

Compared to the control group, Knight-C4 showed two interesting KEGG pathways Herpes
simplex virus 1 infection (p=4.4x10[-03]), a risk factor for AD[52–55] that lead to neuronal damage and
induced gliosis[56,57], in addition to synaptic vesicle cycle (p=4.6x10[-05]) shown to play a key role in
the pathobiology of AD[58] (**Supplementary Fig. 9a**). GO biological process analyses identified
several significant synaptic signaling and transmission pathways (**Supplementary Fig. 9b**).
Furthermore, pathway analyses using significant proteins identified AD-related KEGG pathways
including PI3K−Akt signaling (p=6.5x10[-19]), Rap1 signaling (p=5.8x10[-14]), Axon guidance
(p=2.1x10[-12]), MAPK signaling (p=1.4x10[-20]), and Ras signaling (p=1.8x10[-15]) pathways
associated with the downregulation of Knight-C4 (**Supplementary Fig. 10a**). Top GO pathways
were related to cell/gene regulatory pathways (**Supplementary Fig. 10b**).
314
315 Altogether, these results show that synapse dysfunction is more pronounced in participants with
316 worse cognitive function (late-stage AD).
317
Molecular heterogeneity among AD clusters established neuropathological biomarkers
Our DE analyses identified several known neurodegenerative disease genes dysregulated in
Knight-C4 including *APP, MAPT, CLU, SNAP25, GFAP, SNCA, LRRK2, TARDBP, CHI3L1,*
MMP9, and *C9ORF72* (**Fig. 5a**). The transcriptomics profiles of Synaptosome Associated Protein
25 (*SNAP25*) were significantly downregulated in Knight-C4 (**Fig. 5b**) as has been previously
shown in AD[59], supporting the likelihood of impaired synaptic function in neurons[59]. *SNAP25* has

also been shown as a candidate biomarker in the cerebral spinal fluid (CSF) for synapse

degeneration in AD patients[60]. *SNAP25* was significantly DE between Knight-C4 and control

(p=5.9×10^{-3}, **Fig. 5b**) and between Knight-C4 and other AD cases (p=4.2×10^{-08}, **Fig. 5b**).

However, *SNAP25* was not significantly DE (p > 0.05, **Fig. 5b**) in non-clustered AD cases

compared to the control, which may suggest that synaptic dysfunction in the parietal cortex is not

substantially affected until later stages of AD. The decreased expression of *SNAP25* in Knight-

C4 was replicated in MSBB-C1 and ROSMAP-C1 cohorts (**Supplementary Fig. 11**).

We inspected the results for Glial Fibrillary Acidic Protein (*GFAP*), an emerging biomarker in brain

disorders[61] usually employed to identify astrocytic reactivity state, a process well documented in

AD and neurodegeneration. *GFAP* was overexpressed uniquely in Knight-C4 compared to Knight-

C1-3 (**Fig. 5a,c**, p=1.7×10^{-2}). In spite of the significant astrogliosis of Knight-C4, *GFAP* was not

significantly DE in Knight-C4 compared to controls, nor was it DE in all AD cases compared to

the control (p > 0.05, **Fig. 5c**). To query the possibility that collinearity between case-control status

and cellular population structure introduced spurious results, we repeated these analyses using

a simplified model that did not correct for cellular population structure but could not obtain

significant association. We obtained similar results when we analyzed *AQP4*, another marker

gene of astrocyte reactivity state, as we only detected significant differences in the levels of AQP4

between Knight-C4 and other cases (p=1.0×10^{-02}). In addition, we did not identify significant

differences in *GFAP* proteomic levels (p > 0.05, **Supplementary Fig. 12**), however, proteomic

levels of *GFAP* were significantly upregulated in Knight-C2 (**Supplementary Fig. 12**) compared

to the control and AD brains in Knight-C1,3,4 (p=1.0×10^{-4} and 1.4×10^{-21} respectively). The

increased transcriptomic *GFAP* levels were also identified in the subset of brains with worse

cognitive function from the replication cohorts, MSBB-C1 and ROSMAP-C1 (**Supplementary Fig.**

13). Altogether these results support heterogeneity in the presence of astrocytic reactivity state

and its association with decline of cognition.

Our cross-omics integration analyses also identified cluster-specific dysregulation of Clusterin

(*CLU*), a gene associated with AD[62,63]. Genome-wide associations studies have shown that *CLU*

(also known as APOJ) is the third most associated late-onset AD (LOAD) risk gene after *APOE*

and *BIN1*[63–66]. Proteomic levels of *CLU* were significantly downregulated in Knight-C2 compared

to the control (p=6.4×10^{-3}) and AD cases in Knight-C1,3,4 (p= 9.8×10^{-7}; **Fig. 5d,e**). *CLU* was also

significantly downregulated in Knight-C4 compared to the control (p=3.4×10^{-02}; **Fig. 5e**). To

assess the clinical implications of *CLU* dysregulation, we evaluated its levels in the cerebrospinal

fluid (CSF) from 553 participants of the Knight ADRC by performing survival analyses for

progression using CDR. These analyses indicate that lower CSF *CLU* is associated with an
increased risk of dementia progression (HR=0.42; p=1.0x10^{-07}, **Fig. 5f**). Nonetheless, we did not
observe any significant differences in *CLU* transcriptomic and proteomics levels in the MSBB and
ROSMAP cohorts.

The cross-omics approach identified subset of AD brains with unique abundance levels for AD
biomarkers. These results show the capability of cross-omics approaches in detecting AD
molecular biomarkers that typical non-clustered approaches sometimes miss when AD cases are
analyzed altogether. These results provide support for alternative strategies to reposition
traditional biomarkers for precision medicine approaches.

Metabolic differential abundance analyses identified biological pathways associated with
synaptic dysregulation and cognitive function
We next looked at the significant metabolites that uniquely characterize brain samples in Knight-
C4. To determine whether significant metabolites replicated in additional cohorts, we accessed
metabolomics from the same ROSMAP cohort[36] (**Table 1**, Methods) and performed differential
abundance analyses comparing the levels from donors in the previously identified ROSMAP-C1
cluster to controls and to other AD cases (**Supplementary Table 5**). We identified 57 significant
metabolites (43 increased and 14 decreased) in Knight-C4 compared to controls that replicated
in the ROSMAP-C1 (**Fig. 6a**, **Supplementary Table 9**). Similarly, we identified 74 metabolites
(70 increased and 4 decreased) in the Knight-C4 compared to other AD cases that also replicated
in ROSMAP-C1 (**Fig. 6b**, **Supplementary Table 9**).

Our pathway analyses identified several pathways significantly related to AD. Among the set of
metabolites decreased in AD (**Fig. 6a,b**) gamma-aminobutyrate (GABA) and choline, both
involved in major neurotransmitter pathways, were identified. GABA, synthesized in neurons, was
significantly decreased in Knight-C4 (p= 5.1x10^{-04}) and ROSMAP-C1 (p=1.3x10^{-02}) compared to
the control (**Supplementary Fig. 14a**). The same observation was found when these profiles
were compared to other AD cases (p=1.2x10^{-05} and p= 1.6x10^{-02} for the Knight-C4 and ROSMAP-
C1 respectively, **Supplementary Fig. 14a**). These results support that those cases with worse
cognitive outcomes are associated with dysregulated neuronal or synaptic pathways. As an
inhibitory neurotransmitter, GABA has been shown to play a key role in synchronizing the activity
of the human cerebral cortex[67,68]. Similarly, the metabolomics profiles of choline were decreased
in these profiles in both Knight-C4 (p= 4.1x10^{-06}) and ROSMAP-C1 (p=1.2x10^{-04}) compared to the

control (**Supplementary Fig. 14b**). These reading levels of choline also show significantly
different abundance in these clusters compared to other AD cases (p= $2.9x10^{-07}$ and p=$4.7x10^{-3}$
for Knight-C4 and ROSMAP-C1 respectively, **Supplementary Fig. 14b**). Choline was also shown
to have a critical role in neurotransmitter function because of its effect on the function of
acetylcholine and dopamine[69]. However, we did not find significant differences in the reading
levels of acetylcholine and dopamine. We also did not observe significant differences for
additional neurotransmitters included in the panel (serotonin and glutamate). This indicates that
the dysregulation of neurotransmitters is possibly specific to GABA and choline. We then studied
tryptophan, an amino acid essential for metabolites that serve as neurotransmitters and signaling
molecules[70]. We found that its levels were increased in the Knight-C4 when compared to the
control and other AD cases (p=$8.3x10^{-3}$ and $3.0x10^{-06}$ respectively$^)$ (**Supplementary Fig. 15a**).
Similarly, we found that brains in ROSMAP-C1 showed increased tryptophan levels compared to
the control and other AD brains (p=$1.4x10^{-4}$ and $2.8x10^{-07}$ respectively) (**Supplementary Fig.**
15a)

Furthermore, several increased carbohydrate/sugar metabolites were identified in the set of
metabolites increased in Knight-C4 (**Fig. 6a,b**) including glucose, mannitol, sorbitol, ribose, and
UDP-glucose, indicating a possibility of slower carbohydrate metabolism. As an example,
glucose, a metabolite that has been implicated in the pathogenesis of AD[71,72], was significantly
increased in the Knight-C4 and ROSMAP-C1 (**Supplementary Fig. 15b**). Components of
glycolysis and the tricarboxylic acid (TCA) cycle were also dysregulated in a manner that suggests
decreased glucose metabolism and cellular respiration. Specifically, levels of citrate were
decreased in both Knight-C4 (p= $9.7x10^{-05}$) and ROSMAP-C1 (p= $1.4x10^{-03}$) compared to other
AD cases (**Supplementary Fig. 16a**) indicating possible impaired cellular respiration through the
TCA cycle, which produces citrate. NAD+, an important oxidizing cofactor in glucose metabolism
and cellular respiration, was also decreased in both Knight-C4 (p=$2.2x10^{-02}$) and ROSMAP-C1
(p=$2.2x10^{-02}$) compared to other AD cases (**Supplementary Fig. 16b**). NAD+ is synthesized from
tryptophan, and levels of NAD+ have been shown to decrease with age, potentially contributing
to the pathogenesis of AD[73]. This decreased availability of NAD+ could also contribute to impaired
glucose metabolism. These observations are in line with previous findings that associate
increased brain glucose and slowed glucose metabolism with more severe AD[72,74].

In addition, several increased sphingolipid metabolites were identified (**Fig. 6a,b**). Previous
studies showed the implication of sphingolipid metabolism deregulation in AD[75]. For instance,

sphingosine, found to have higher levels in AD brains[75], showed significantly increased
metabolism levels in both Knight-C4 and ROSMAP-C1 (**Supplementary Fig. 16c**).

429
430 Together, these results further characterize the molecular profiles in this subset of AD brains and
431 show synaptic/neuronal dysregulation association and also possible comorbidity between AD and
432 other diseases such as diabetes[74] illustrated by the increased carbohydrate/sugar metabolites in
433 this subset.

434
Single-cell data suggests that pathways in different cell types are more prominently altered
in distinct molecular profiles of AD
We studied the cell type specific pathways altered in the AD profiles by leveraging single-nuclei
RNA-seq from a subset of the Knight ADRC participants. We selected the top 5% of genes that
showed the most specific cell-type expression profile in neurons, astrocytes, oligodendrocytes,
oligodendrocyte precursor cells (OPC), and microglia. Then, we used this information to
determine if any AD molecular profiles showed a stronger signature of cell-type specific
dysregulation. These analyses showed that Knight-C4 was enriched in genes overexpressed in
astrocytes and endothelial cells (38% and 23% for all hits respectively; **Fig. 7a-left panel** and
Table 4). KEGG pathways analyses of astrocytic genes identified astrocyte-related pathways
(**Fig. 7b**) including Axon guidance (p=2.8x10^{-05}), and Hedgehog signaling pathway (p=1.6x10^{-06}).
Previous work has shown the role of astrocytes in axon guidance during development and repair[76]
and hedgehog signaling pathways involved in neuroinflammation, neuronal cell differentiation,
and neuronal death[77]. Many of these pathways were also enriched in overexpressed genes in
endothelial cells (**Supplementary Fig. 17a**).

450
Knight-C4 was also enriched in genes downregulated in microglial and neuronal genes (**Fig. 7a-**
right panel and **Table 4**). Neuronal genes showed an association with synaptic/neuronal-related
pathways (**Fig. 7c-d**), including Synaptic vesicle cycle (p=1.0x10^{-06}), Retrograde
Endocannabinoid Signaling (p=3.6x10^{-03}) key modulators of synaptic function[78–80], and Gap-
junction (p=2.2x10^{-02}) formation known to play an essential role in intercellular metabolic
communication and transmission across electrical synapses[81]. Microglial downregulated genes
implicated AD related pathways including Phagosome (p=1.0x10^{-06}), Herpes simplex virus 1
infection (p=2.0x10^{-04})—previously associated with AD risk[52–55] leading to neuronal damage and
induce gliosis[56,57], Gap junction (p=2.2x10^{-02}), and AD (p=5.4x10^{-08}) (**Supplementary Fig. 17b**).
Further explorations showed that Knight-C4 is significantly enriched in downregulated genes

related to homeostatic microglia, including C-X-3-C Motif Chemokine Receptor 1 (*CX3CR1*; p=

5.10x^{-03}, **Fig. 7e,f**) and purinergic receptor P2Y13 (*P2RY13;* p=1.2x10^{-2}, **Fig. 7e,f**).

Additionally, we identified genes dysregulated in specific clusters and cell types, including the

TP53 induced glycolysis regulatory phosphatase (*TIGAR*) overexpressed in microglia and

upregulated in Knight-C1 (**Fig. 7e,f**). TIGAR is a p53-inducible protein that regulates energy

metabolism and oxidative stress. Among the upregulated endothelial-specific genes in Knight-C1,

we identified *MYOCD*, *CNN1*, *PLN*, *MYH11*, S*100A4*, *SLC13A4*, *DES*, implicating pathways

associated with cell cycle, junction, anion transport, Aβ clearance and actin. In particular, *MYH11*,

overexpressed in Knight-C4 (**Fig. 7e,f**), has been reported to be associated with the risk of

dementia[82]. Moreover, oligodendrocyte-specific genes dysregulated in Knight-C2 include *STX4*,

ACTN4, and *FBXO32* relating to pathways associated with vesicle docking, neural tube, junction,

apoptosis and actin. Particularly, Syntaxin-4 (*STX4*), upregulated in Knight-C2,4 (**Fig. 7e,f**), is

critical for vesicle docking and the Wnt frizzled receptor (*FZD9*) and coreceptor (*LRP5*), which

regulate the synaptic vesicle cycle[26]. *STX4* has also been shown as one of the disease risk genes

in AD[83].

These results suggest that different pathways mediate distinct molecular profiles of AD in multiple

cell types.

Integrative cross-omics analyses identified reduced transcript levels of SNCA across
multiple brain regions in AD participants with worse cognitive function

Transcriptomic and proteomic assays showed *SNCA* (alpha-synuclein) was among the top

molecules that best discriminate Knight-C4 versus Knight-C1-3 molecular profiles. Our results

show that *SNCA* transcriptomic levels were significantly downregulated in Knight-C4 compared

to Knight-C1-3 (p= 2.0x10^{-05}) and control brains (p=2.2x10^{-02}; **Fig. 8a**). Interestingly, we did not

observe a significant association (p > 0.05) in non-clustered AD compared to the control (**Fig. 8a-**

left panel). This suggests that *SNCA* levels in the parietal cortex may be altered only in late-stage

AD. Alpha-synuclein (αSyn) protein levels were marginally downregulated in brains from Knight-

C4 (**Fig. 8b**) compared to the control (p=5.16x10^{-02}) and significantly lower in Knight-C2 compared

to the control (p=7.8x10^{-5}) and Knight-C1,3,4 (p=6.2x10^{-09}).

We also identified downregulation of *SNCA/*αSyn in MSBB-C1 (**Fig. 8c,d**) compared to the

controls (p=1.8x10^{-02} and p=1.0x10^{-05} for transcriptomics and proteomics respectively). Similarly,

SNCA levels in MSBB-C1 were significantly lower compared to other AD (p=1.0x10^{-02} and

p=3.4x10^{-03} for transcriptomics and proteomics respectively, **Fig. 8c,d**). However, no significant

differences in transcriptomic or proteomic levels in the additional donors (MSBB-C2) were

observed (p > 0.05, **Fig. 8c,d**). Moreover, the downregulation of *SNCA* in the MSBB-C1 donors

was also seen in the frontal pole (BM10), superior temporal gyrus (BM22), and inferior frontal

gyrus (BM44) brain regions from the same study (**Supplementary Fig. 18a-c**). Similarly, *SNCA*

transcriptomic levels were significantly downregulated in ROSMAP-C1 (**Fig. 8e**) compared to the

control (p=3.5x10^{-02}) and other AD cases (p=4.5x10^{-03}).

The downregulation of *SNCA* in Knight-C4 further supports the association of this profile with

synaptic dysfunction. S*NCA* encodes α-synuclein (αSyn), an abundant presynaptic protein that

plays a role in regulating synaptic vesicle trafficking and subsequent neurotransmitter

release[84][PMID:7646890]. αSyn itself is released from neurons via multiple cell biological

mechanisms including exocytosis and is detectable in the extracellular space as a monomer and

pathologically aggregated species[85–87]. Mutations in *SNCA*, overexpression of wildtype αSyn, and

injection of pre-formed aSyn fibrils (PFFs) are sufficient to cause neuropathology and

parkinsonian syndromes in both humans and animal models[88–94].

To further study synapses in a model of pathological αSyn aggregation, we integrated and

analyzed NanoString gene expression data (see Methods) generated from a panel of 807 gene

transcripts measured in brain tissue of A53T αSyn transgenic mice crossed onto *APOE*

backgrounds[95]. Of the 807 genes included in the panel, 89 (11%) were classified as synaptic

genes (SynGO consortium[37]). We performed DE analysis to compare mice with high pSyn

pathology (defined as > 5% coverage by IHC) to mice with low pathology (< 5% coverage by IHC,

see Methods) and identified 255 DEGs, including 13 synaptic genes. We then interrogated which

of synaptic genes in DE in Knight-C4 were also dysregulated in the A53T αSyn-APOE transgenic

mice (**Supplementary Fig. 19**). We identified that all of the 13 genes identified in the mouse

model were also dysregulated in Knight-C4 compared with other AD cases (Fisher p=3.6x10^{-09})

(**Supplementary Fig. 19a**). These results suggest that the profile of Knight-C4 might be driven

by synaptic dysregulation. When comparing to the control, only five synaptic genes were shared

between the three datasets (**Supplementary Fig. 19b**). These findings were limited by the fact

that the NanoString panel contains only 12% of the significant genes in Knight-C4.

Altogether, these results provide more evidence of the association of Knight-C4 with synaptic
dysfunction, and suggest that the lower levels of soluble *SNCA* observed in this profile with worse
cognitive function in multiple brain regions may be associated with αSyn (Lewy body) pathology
which is present in 50-60% of AD brains[96–98].

532
Discussion
In the current study, we leveraged machine learning approaches to integrate high-throughput
multi-omics datasets from AD cases in multiple cohorts and brain regions. Our analyses led us to
identify multiple molecular profiles, genes/pathways, and cellular population structures affected in
specific AD cases. We found a distinct molecular profile associated with worse cognitive function,
earlier age at onset/death, and dysregulated neuronal/synaptic pathways in the parietal cortex.
Our results suggest that this molecular profile captures additional neuropathological events not
fully captured by β-amyloid or tau staging as previously reported[99,100]. Similar to previous studies[8],
we did not find a significant association between any molecular profile and APOE ε4 or PRS,
suggesting that these molecular profiles are not driven by genetic factors associated with genetic
AD risk. We also determined, through an exhaustive replication, that this molecular profile is also
present in multiple brain regions from the MSBB and ROSMAP cohorts. Further, we demonstrated
that in each of these studies, this molecular profile is associated with worse clinical and cognitive
function, offering new insights into the molecules that may wax or wane as cognition declines.

547
Notably, we observed that these donors with worse cognitive function showed a significantly
increased proportions of astrocytes and reduced proportions of neurons. This might indicate a
neuronal loss at later stages of AD, leading to the development of severe cognitive impairment.
Consistent with these findings of gliosis and neuronal loss, we found that the molecular profile of
this subset of participants is significantly enriched in dysregulated synaptic genes, which may
reflect greater synaptic losses in participants with worse cognitive function. Furthermore, we
identified dysfunction of several neuronal and synaptic pathways that are significantly associated
with this profile including dopaminergic synapse and glutamatergic pathways. Although the
involvement of dopamine in AD is still debatable, several studies have shown an association
between AD pathologies (e.g. Aβ deposition) and the dopaminergic dysfunction[101–109]. Similarly,
glutamatergic synapse is a major excitatory neurotransmitter in the central nervous system (CNS)
that regulates several neuronal functions. Increasingly evidence has demonstrated an association
between glutamate alterations and AD pathology[110–113]. Moreover, metabolic differential
abundance analyses identified significant metabolites associated with biologically relevant AD

pathways, most of which are related to major neurotransmitter pathways. This may suggest that
donors in this profile have a more profound neuronal or synaptic dysregulation. These brains also
exhibit a metabolic profile associated with disease duration, supporting its implication in later
stages AD. Altogether, these results suggest that these donors have a more prominent synaptic
loss and dysfunction associated with worse cognition and advanced AD indicating the feasibility
of our approach in identifying molecular changes that occur at late-stage AD. These novel
molecular findings can be leveraged to identify new biomarkers and potentially therapeutic targets
– not necessarily related to amyloid and tau – that might be effective in later stages of disease,
when therapeutics targeting amyloid seem to be not effective.

Our subsequent transcriptomic and proteomic differential expression analyses showed a
significantly higher number of hits associated with this profile. Further investigations showed that
many of the genes detected in this profile were neuronal/synaptic genes. Among these, we
identified *SNAP25* downregulated in this profile in the discovery and replication cohorts. *SNAP25*
is implicated in several physiological pathways and neuropathologies, including AD and Down
syndrome (DS)[59]. Transcriptomic and proteomic DE analyses also identified several genes
associated with AD including *GFAP* and *CLU* that are more noticeably dysregulated in the distinct
profiles. These two genes were not significantly altered in non-clustered AD cases compared to
controls. Increased astrocyte reactivity and overexpression of *GFAP* has been reported in multiple
studies[61,114–121]. For instance, Greber *et al*., 1999[59], showed that elevated expression of *GFAP* was
found in multiple brain regions including frontal, parietal, temporal and occipital cortex regions of
AD patients[59]. In addition, we leveraged CSF proteomics and longitudinal clinical evaluations to
show that lower levels of CSF *CLU* are associated with increased risk of dementia progression in
an extended cohort from the Knight ADRC. Multiple studies have shown the ability of *CLU* to play
a neuroprotective role in AD by altering Aβ aggregations and promote Aβ clearance[66,122–125]. More
recently, additional studies have identified *CLU* as mediator regulating Aβ-induced
neurotoxicity[66,126,127]. The heterogeneity among AD cases opens the possibility to develop novel
approaches using these and additional genes for biomarkers for precision medicine approaches.
590

By integrating single-nuclei RNA-seq, we extracted additional insights that support distinct patters
of cell types implicated in molecular AD profiles. For instance, we determined that *CX3CR1*, a
homeostatic microglia gene, is significantly downregulated in Knight-C4. The lower expression of
CX3CR1 may indicate loss of homeostatic microglia, leading to neuronal damage and loss. The
association between homeostatic microglia function and the degree of neuronal cell loss has been

shown to be linked to AD[128]. More recently, the loss of *CX3CR1* was shown to be associated with
microglial dysfunction illustrated by dampened TGFβ-signaling, increased oxidative stress
responses, and dysregulated pro-inflammatory activation[129]. However, we could not determine a
significant overexpression of microglia activated genes, nor replicate this in additional cortical
regions.

Our results highlight the utility of integrating multi-omics and indicate that cross-omics signatures
can better capture differences and discriminate molecular variations in complex and
heterogenous diseases such as AD. An increasing body of evidence endorses broad clinical and
neuropathological heterogeneity among individuals with AD. Similarly, there is evidence that
molecular profiles differ substantially within AD[5]. Recognizing this heterogeneity is highly
important as the *statistical noise* introduced by molecular heterogeneity within a population has
potential to conceal dysregulated pathways and risk biomarkers that might be altered in only
subsets of the AD general population. Therefore, identifying cross-omics molecular profiles of AD
and their molecular signatures, including genes and pathways, may extract new insights into AD
and provide a platform to identify novel treatments and biomarkers and eventually be used toward
precision medicine.

We identified that alpha-synuclein is among the top molecules that better discriminate AD profiles.
We demonstrated that the transcriptomic/proteomic levels of *SNCA* were under-expressed in a
subset of AD cases with more advanced tau pathology and worse cognition and replicated this
finding in several cohorts and brain regions. Alpha-synuclein is the major constituent of Lewy
bodies, the histopathologic hallmark of PD and DLB. LB pathology is also present in a majority of
advanced AD cases, including autosomal dominant AD and DS[96,97,130–134]. In addition, previous
work has demonstrated the relationship between alpha-synuclein and AD pathologies including
Aβ plaques and tau aggregations using different mouse models[135,136] and implicated alpha-
synuclein pathology in neuronal/synaptic dysfunction and death[137,138]. Despite the substantial
efforts in studying the association between this protein and AD pathology, the mechanism by
which alpha-synuclein contributes to the pathogenesis and progression of AD remains elusive.
Several regulatory mechanisms that contribute to *SNCA* levels have been proposed. For instance,
previous studies based on primary neuronal cultures[87], mice models[139], and live cell imaging[140]
have shown that the neuronal or synaptic activities regulate the aggregation of *SNCA*. The
downregulation of *SNCA* in a subset of AD cases with unfavorable outcomes suggests that *SNCA*
might be a marker of neuron/synapse losses that can be used for identifying AD stages.

Although this work provides new insights for understanding the genetic and molecular
heterogeneity in AD brains, additional work is needed to further validate and better understand
the role of key drivers of these profiles using model organisms (e.g., mouse models). Therefore,
future studies analyzing longitudinal data from mouse models and longitudinal CSF/plasma from
large cohorts can certainly provide novel insights into the role of synaptic dysregulation in AD,
and the possible implication in additional neurodegenerative diseases. Additional work is also
needed to investigate the possible role that alpha-synuclein in AD, and its association with worse
cognitive function. In addition, this work has promising implications in drug repositioning and
staging biomarkers that may lead to identify novel therapeutic potentials for AD and therefore
bring AD a step closer to precision medicine care and treatment.
640
641 **Methods**
642
643 **Study Cohorts**
644
Discovery (Knight ADRC)
Frozen postmortem parietal lobe tissue samples from Knight Alzheimer Disease Research Center
(Knight ADRC) participants, collected with informed consent for research use, were provided by
the Knight ADRC Neuropathology Core. Analysis of these samples was approved by the
institutional review board of Washington University in St. Louis. Only sporadic AD participants
and controls with transcriptomics, proteomics, and metabolomics data available were included in
this study, resulting in 255 sporadic AD and 23 controls.
652
- **RNA-seq**
The data generation for the RNA-seq dataset has been previously described[29–31]. Briefly,
total RNA was extracted from frozen parietal cortex tissue using a Tissue Lyser LT and
purified using RNeasy Mini Kits (Qiagen). The Nanodrop 8000 (Thermo Scientific) and
TapeStation 4200 (Agilent Technologies) were used to perform quality control of the
RNA's concentration and purity, and degradation. The RNA integrity number (RIN) was
calculated using an RNA 6000 Pico assay on a Bioanalyzer 2100 and TapeStation 4200
(Agilent Technologies). The software determines the RINe on the Bioanalyzer and
TapeStation taking into account the entire electrophoretic trace of the RNA, including the
presence or absence of degradation products. The DV200 value is defined as the
percentage of nucleotides greater than 200nt. All cDNA libraries were prepared using a
TruSeq Stranded Total RNA Sample Prep with Ribo-Zero Gold kit (Illumina) and

sequenced on an Illumina HiSeq 4000 using 2 x 151 paired-end reads at the McDonnell
Genome Institute at Washington University in St. Louis. The average number of reads per
sample was 43,195,080.

- **Proteomics**

669   Proteomic data from the Knight ADRC were generated on the SomaLogic platform
670   (SomaLogic Operating Co., Inc., Boulder, CO) from frozen parietal cortical tissue samples
671   (~500mg) and CSF samples. The SomaLogic platform is a multiplexed, aptamer-based
672   protein quantification platform[141]. The platform measured 1,305 aptamers in total. Full
673   details of the proteomic data generation have been described previously[32].

- **Metabolomics**

Metabolomic data from the Knight ADRC were generated on the Metabolon Precision
Metabolomics™ UPLC-MS/MS platform (Metabolon, Inc., Morrisville, USA), from 50mg
frozen parietal cortical tissue samples. The platform measured 880 metabolites from nine
"super pathways": amino acids, carbohydrates, cofactors and vitamins, energy, lipids,
nucleotides, peptides, xenobiotics, and partially characterized molecules. Metabolon
provided structural identity annotations for 815 metabolites; the remaining 65 were
excluded from the final dataset. Full details of the metabolomics data generation have
been described previously[33].

- **Single-nuclei (snRNA-seq)**

The data generation of snRNA-seq has been previously described in[142,143]. Briefly, 74
frozen parietal tissues were processed according to the 'Nuclei extraction and library
preparation' protocol described in[142]. In this protocol, the tissue was homogenized, and
the nuclei were isolated using a density gradient. The nuclei were then sequenced using
the 10X Chromium single cell Reagent Kit v3, with 10,000 cells per sample and 50,000
reads per cell for each of the 74 samples.

Replication (MSBB, BM36)

- **RNA-seq**

The RNA-seq raw data from The Mount Sinai Brain Bank (MSBB) study was downloaded
from the Synapse portal (syn3157743). It is publicly available as part of the Accelerating
Medicines Partnership for Alzheimer's Disease (AMP-AD). In brief, this data were
generated and sequenced from RNA extracted from four postmortem brain regions,
including frontal pole (BM10), superior temporal gyrus (BM22), parahippocampal gyrus
(BM36), and inferior frontal gyrus tissue (BM44) from 313 subjects. RNA-seq libraries were

prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, CA).
The rRNAs were depleted using the Ribo-Zero rRNA Removal Kit (human/mouse/rat)
(Illumina). Single-end non-standard reads of 101bp were generated by Illumina HiSeq
2500 (Illumina)[35]. The average number of reads per sample was 32,201,200. RNA-seq
data from region parahippocampal gyrus (BM36) was selected for the cross-omics
integration approach because of the availability of proteomics data. Data from the
remaining regions were used to explore the identified profiles' expression profiles to
determine whether these are consistent across cortical brain regions.

- **Proteomics (TMT)**
The proteomics TMT data were obtained from the AMP-AD Synapse portal (syn25006650)
processed by Johnson *et al.*, 2022[144]. The raw proteomic TMT data is publicly available
at AMP-AD and can be downloaded from Synapse portal (syn21347564). In short, before
TMT labeling, the 198 samples were randomized by co-variates (protein quality, sample
concentration, diagnosis, age, and sex) into 20 batches (10 cases per batch). The
digested peptides were resuspended in 50 mM HEPES (pH 8.5) and labeled with the TMT
11-plex kit (Thermo Fisher) according to the manufacturer protocol. In each batch, GIS
samples were labeled using TMT channel 126. All 11 channels were mixed equally,
desalted with a 100 mg C18 Sep-Pak column (Waters) for the subsequent
fractionation[144,145].

Replication (ROSMAP, DLPFC)
- **RNA-seq**
The RNA-seq raw data from The Religious Orders Study and Memory and Aging Project
(ROSMAP) Study was downloaded from the Synapse portal (syn17008934) available from
AMP-AD. Briefly, RNA-seq samples were extracted using Qiagen's miRNeasy mini kit (cat.
no. 217004) and the RNase-free DNase Set (cat. no. 79254) and quantified by Nanodrop.
Agilent Bioanalyzer evaluated quality. Library preparation was performed by poly-A
selection followed by first strand-specific cDNA synthesis, then dUTP for second strand-
specific cDNA synthesis followed by fragmentation and Illumina adapter ligation for library
construction. Paired-end read sequences with a length of 101bp were generated by
Illumina HiSeq. Fifty-seven samples were submitted later to the platform and run on an
updated protocol (batch 2 protocol). For consistency, we removed those samples from this
cohort. The average number of reads per sample was 47,434,600. Only No Cognitive
Impairment (NCI) and AD with NO other cause of cognitive impairment cases were used

in this study. All cases with "unknown" BraakTau scores were discarded. Plaque density
and Neurofibrillary tangle burden (PHF tau tangles) are a summary of a AD pathology
derived from three AD pathologies: neuritic plaques, diffuse plaques, and neurofibrillary
tangles based on five regions: midfrontal cortex, midtemporal cortex, inferior parietal
cortex, entorhinal cortex, and hippocampus. Tangles are identified by molecularly specific
immunohistochemistry based on the mean of eight regions: tangles_hip (hippocampus),
tangles_ec (entorhinal cortex), tangles_mf (midfrontal cortex), tangles_it (inferior
temporal), tangles_ag (angular gyrus), tangles_calc (calcarine cortex), tangles_cg
(anterior cingulate cortex), angles_sf (superior frontal cortex).

- **Metabolomics**

Data from the Religious Orders Study and Memory and Aging Project (ROSMAP) were
generated by the Duke Metabolomics and Proteomics Shared Resource, a member of the
ADMC, using protocols published previously for blood samples[146–148]. A custom protocol
developed for the brain samples can be found on Synapse at syn10235609. The
dorsolateral prefrontal cortex (DLPFC) metabolomic data from the ROSMAP studies
quantified on the Metabolon Precision Metabolomics platform and preprocessed by the
ADMC as described in[149] were downloaded from Synapse in July 2021 (syn25878459).
The platform measured a total of 1,055 metabolites in the ROSMAP dataset.

749
Data processing
RNA-seq QC, alignment, and gene expression quantification: All RNA-seq datasets from the
discovery and replication were processed and aligned using our in-house RNA-seq pipeline
(https://github.com/HarariLab/RNA-seq-Pipeline). Genome reference and gene models were
selected similar to the TOPmed pipeline (https://github.com/broadinstitute/gtex-
pipeline/blob/master/TOPMed_RNAseq_pipeline.md). Reference genome GRCh38 and
GENCODE 33 annotation, including the addition of ERCC spike-in annotations, were used. We
excluded ALT, HLA, and Decoy contigs from the reference genome due to the lack of RNA-seq
tools that properly handle these regions. Before alignment, the quality of raw read sequences for
all libraries was assessed using FastQC (v0.11.9)[150]. All raw read sequences were then aligned
to the human reference genome (GRCh38) using STAR (v.2.7.1a)[151]. The alignment quality was
evaluated using sequencing metrics such as reads distribution, ribosomal content, or alignment
quality provided by STAR using Picard tools (v.2.8.2)[152]. All samples that failed to pass the QC or
were outliers (Knight ADRC=9, MSBB=18, ROSMAP=6) were removed from the downstream
analyses. Raw read counts for transcripts and genes were generated using STAR and computed

transcript/gene expression levels as normalized in FPKM (Fragments Per Kilobase of transcript
per Million mapped reads) format.

Metabolomics QC and Quantification: Metabolomics data from Knight ADRC and ROSMAP were
processed similarly. Full details of the QC process have been previously described[153]. Briefly, 188
metabolites with readings missing in over 20% of donors were excluded, readings were log10-
transformed, means per metabolite were adjusted to zero, and outlier readings (outside 1.5xIQR)
were excluded. Missing values for metabolites in < 20% of donors were replaced by their mean
value. No samples were removed due to the missingness rate. Principal component analysis was
performed with the FactoMineR R package[154] to identify outlier samples; four outlier samples were
excluded. The final dataset consisted of 627 metabolites. A similar procedure was used to clean
the ROSMAP metabolomic dataset. Metabolites without assigned structural identities and
metabolites with greater than 20% missing readings were excluded, readings were log10-
transformed, the mean of each metabolite's distribution was adjusted to zero, and outlier readings
were removed. Two samples missing greater than 20% of readings were excluded. The final
dataset consisted of 595 metabolites.

Proteomics QC and Quantification: Proteomic data for brain and CSF samples from the Knight
ADRC were first filtered based on a limit of detection (LOD). Samples with greater than 15%
outlier analytes (analyte readings below the LOD) were excluded. Analytes were then filtered
based on scale factor difference, meaning the absolute value of the maximum difference between
the calibration scale factor per aptamer and the median for each plate run. Analytes were
excluded if their scale factor difference exceeded 0.5. Based on log10-transformation of protein
readings, samples exceeding 1.5-fold of the interquartile range (IQR) per analyte were considered
outliers. Analytes with greater than 15% outlier samples were excluded. Similarly, samples that
were outliers for greater than 15% of analytes were excluded. Full details of the proteomic data
QC have been described previously[32]. Missing analyte readings and removed outlier readings
were imputed using the impute.knn function from the impute R package (v1.56.0)[155]. A plate-wise
batch correction was performed using the ComBat function from the sva R package (v3.30.1)[156].
The final brain dataset consisted of 1,092 analytes, and the final CSF dataset consisted of 713
analytes. Before using this data, analytes with missing expressions in > 20% of donors were
excluded, and missing expressions of those in < 20% were replaced with their mean value.

The processed data for TMT proteomics from MSBB BM36 was obtained from AMP-AD
(syn25006647) and processed by Johnson *et al.*,2022[144]. In brief, 760 raw files generated from
19 TMT 11-plexes were analyzed using the Proteome Discoverer suite (version 2.3, Thermo

Fisher Scientific). The UniProtKB human proteome database containing Swiss-Prot and TrEMBL

human reference protein sequences was used to search mass spectra. Peptide spectral matches

and peptides were filtered to a false discovery rate (FDR) of less than 1% using Percolator

software. After spectral assignment, peptides were assembled into proteins and were further

filtered based on the combined probabilities of their constituent peptides to a final FDR of 1%[144].

Unique and razor (that is, parsimonious) peptides were considered for quantification. TMT

reporter abundance was transformed into a ratio followed by log_2 transformation. Quality control

analysis was performed, and outliers were removed. Similar to the Knight ADRC, analytes with

missing expressions in > 20% of donors were excluded, and missing expressions of those in <

20% were replaced with their mean value.

<u>Single-nuclei (snRNA-seq) QC, alignment, and gene expression quantification</u>: Full details of the

data process of snRNA-seq data have been previously described in [142,143]. In short, CellRanger

(v2.1.1 10XGenomics)[157] software was employed to align the sequences and quantify gene

expression. Read sequences were aligned to a custom pre-mRNA reference constructed from

genome assembly GRCh38 and generated as described by 10X Genomics technical manual.

Filtering and QC analyses were performed individually using the Seurat package (v2.20 and 2.30)

on each subject. All nuclei with high mitochondria gene expression were removed and only genes

expressed in > 3 cells were kept for downstream analysis. Cells with < 1800 or > 8000 genes

expressed in them were excluded. The data were normalized using the *LogNormalize* function

that normalizes the gene expression measurements for each cell by the total expression, scales

by a factor equal to the median counts of all genes, and log-transforms the expression.

Clustering of AD participants

To cluster AD participants, iClusterBayes (Integrative clustering of multiple genomic data types)[34]

available from iClusterPlus R package (v1.22.0)[158] was employed. For each integration process,

shared samples across omics datasets were extracted, and the top 2000 most variant features

were selected. iClusterBayes was performed by fitting multiple Bayesian models using a different

number of clusters ranging from 1 to 10. W ran 22,000 Markov Chain Monte Carlo (MCMC)

iterations for each, of which the first 12,000 were discarded as burn-in. The prior probability for

the indicator variable gamma of each data set was set to 0.1, whereas the posterior probability

cutoff was set at 0.5. The standard deviation of the random walk proposal for the latent variable

was set to 0.5. The remaining parameters were left with the default values.

Cell proportion analysis

CellMix R package (v1.6.2)[159], employed multiple digital deconvolution methods, was used to
estimate cellular population structure from gene expression data (TPM) generated by the Salmon
quantification tool. The machine learning model and the gene panel (genes marker expressed
highly in specific cell types) previously described in[31]. Four cell types, astrocytes, microglia,
neurons, and oligodendrocytes, were tested using two algorithms, meanProfile[159] and ssNMF
(semi-supervised nonnegative matrix factorization)[160]. The significant difference in cell proportion
between clusters was computed using a generalized linear model (GLM) test and corrected by
sex and age of death (AOD).

838
Differential expression analysis of AD clusters
RNA-seq: differential expression (DE) analyses were performed to compare subjects in each
cluster to the control subjects as well as other AD subjects using the DESeq2 R package
(v.1.22.2)[161]. Our models were adjusted for sex, age at death, and the percentage of astrocytes
and neurons. To enhance our confidence in the differentially expressed genes we discovered,
lowly expressed genes were removed. Only genes with expression > 0.5 CPM (count per million)
in at least 25% of samples in either group being compared were retained for downstream
analyses. The false discovery rate (FDR) was estimated using Benjamini-Hochberg (BH)[162]. All
genes with FDR < 0.05 were considered differentially expressed genes.

Proteomics: differential expression analyses between clusters were carried out with linear models
(R function glm) with age at death and sex as covariates. P-values were adjusted using Benjamini-
Hochberg (BH)[162].

Metabolomics: differential abundance analyses were also carried out with linear models, with age
at death, sex, and post-mortem interval (PMI) as covariates. P-values were adjusted using
Benjamini-Hochberg (BH)[162].

Single-nuclei: differential expression analyses were performed to compare the overexpression of
each gene in each cell-type relative to other cell types using glmmTMB R Package (v1.1.3). This
approach fits generalized linear mixed models using a template builder (glmmTMB). Our model
was corrected by sex covariate. To ensure cell-type specific overexpression, for each cell type,
only top genes whose effect size is greater than 90% percentile cutoff were retained for
downstream integration analyses.

860
Survival analyses

Kaplan-Meier survival analyses and Cox proportional hazards models were used to determine the

association of different clusters with survival outcomes and also to determine the association with

the risk of dementia progression using survival (v3.2-3)[163] and surviplot (v1.1.1)[164] R packages.

Significance of overlap

The significance of overlap for all analyses was computed using Fisher's exact test available

from the R stats package (v4.3.0)[165].

Pathway Analysis

All pathway analyses for transcriptomics and proteomics were performed using the EnrichR R

package (v3.0)[166] using genes/proteins significantly up-and downregulated between clusters vs.

control and between distinct clusters. Two widely used databases, gene ontologies (GOs), related

to molecular function, biological process, and cellular components, and KEGG databases were

used. All pathways with an adjusted p-value < 0.05 were considered statistically significant.

Similar pathways analyses were performed for single-nuclei (snRNA-seq) using EnrichR using

significantly up-and downregulated genes in specific cell types. For metabolomics, pathways

analyses were performed using MetaboAnalyst (v5.0) software[167] using the metabolites that were

increased- and decreased between clusters and the control and across clusters.

880
Replication analysis

Our replication strategy was designed to focus on the molecular profiles identified in the discovery

analyses of the Knight ADRC cohort by extracting the significant genes and proteins identified in

the Knight ADRC cohort. Using this set of features, iClusterBayes was run on both datasets

(MSBB and ROSMAP) using the same parameters used with the discovery cohort.

NanoString gene expression analysis

The data generation and full details of the QC processes have been previously described[95].

Briefly, A53T αSyn-Tg mice were crossed with human *APOE2*, *APOE3*, or *APOE4* knockin mice

or *Apoe* knockout mice to generate A53T mice homozygous for one of the three human alleles or

completely null for *Apoe*. Sample sizes and genotypes for NanoString gene expression analysis

were selected on the basis of αSyn pathology and biochemistry results. RNA was isolated from

12-month old A53T/EKO (n=10), A53T/E2 (n=2), and A53T/E4 (n=10) mouse midbrain. 793

transcripts were quantified with the NanoString nCounter multiplexed target platform using a

customized chip based on the Mouse Neuroinflammation panel (www.nanostring.com). The

geometric mean of negative control lanes was subtracted from gene transcript counts, and gene
expression data were normalized to the geometric mean of positive control lanes and a list of
housekeeping genes[95]. QC analyses including principal components analysis were performed
using nSolver 4.0 and the Advanced Analysis 2.0 plugin (NanoString). For differential expression
analysis, pSyn pathology was expressed as low (< 5% coverage by IHC) or high (> 5% coverage
by IHC) for each animal, and APOE genotype and pSyn pathology were selected as predictor
covariates. Differentially expressed analyses were performed using linear regression models in
R with sex as covariates. P-values were adjusted using Benjamini-Hochberg (BH)[162].

904
Data availability
Transcriptomics data from the Knight ADRC are available by request from the National Institute
on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) with accession
number ng00083 (https://www.niagads.org/datasets/ng00083). Proteomics data from the Knight
ADRC donors are available at the NIAGADS Knight ADRC collection with accession number
ng00102 (https://www.niagads.org/datasets/ng00102). Metabolomics data from the Knight
ADRC are available at the NIAGADS Knight ADRC collection with accession number NG00113
(https://dss.niagads.org/datasets/ng00113/). The single nucleus data from the Knight ADRC are
available at NIAGADS Knight ADRC collection with accession number NG00108
(https://dss.niagads.org/datasets/ng00108/). MSBB transcriptomics and proteomics data are
publicly available at Synapse under Synapse IDs syn3157743
(https://www.synapse.org/#!Synapse:syn3157743) and syn25006650
(https://www.synapse.org/#!Synapse:syn25006650) respectively. ROSMAP transcriptomics and
metabolomics data are publicly available at Synapse under Synapse IDs syn17008934
(https://www.synapse.org/#!Synapse:syn17008934) and syn25878459
(https://www.synapse.org/#!Synapse:syn25878459) respectively.

921
922　**Code availability**
923　The analysis code used for this study will be available at the time pf publication.

924
References

1. Alzheimer's A. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement*.
2021;17:327-406.

2. Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in
Alzheimer's disease. *Nat Med*. 2021;27(5):871-881.

3. Jellinger KA. Pathobiological subtypes of Alzheimer disease. *Dement Geriatr Cogn Disord*.
2020;49(4):321-333.

4. Collij LE, Salvadó G, Wottschel V, et al. Spatial-temporal patterns of β-amyloid accumulation:
a subtype and stage inference model analysis. *Neurology*. 2022;98(17):e1692-e1703.

5. Neff RA, Wang M, Vatansever S, et al. Molecular subtyping of Alzheimer's disease using
RNA sequencing data reveals novel mechanisms and targets. *Sci Adv*. 2021;7(2):eabb5398.

6. Tijms BM, Gobom J, Reus L, et al. Pathophysiological subtypes of Alzheimer's disease
based on cerebrospinal fluid proteomics. *Brain*. 2020;143(12):3776-3792.

7. Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: A systematic
review and meta-analysis. *Neurology*. 2020;94(10):436-448.

8. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically
defined subtypes of Alzheimer's disease: a case-control study. *Lancet Neurol*.
2012;11(10):868-877.

9. Whitwell JL, Graff-Radford J, Tosakulwong N, et al. [18F] AV-1451 clustering of entorhinal
and cortical uptake in Alzheimer's disease. *Ann Neurol*. 2018;83(2):248-257.

10. Byun MS, Kim SE, Park J, et al. Heterogeneity of regional brain atrophy patterns associated
with distinct progression rates in Alzheimer's disease. *PloS One*. 2015;10(11):e0142756.

11. Choi M, Youn H, Kim D, et al. Comparison of neurodegenerative types using different brain
MRI analysis metrics in older adults with normal cognition, mild cognitive impairment, and
Alzheimer's dementia. *PloS One*. 2019;14(8):e0220739.

12. Abeshouse A, Adebamowo C, Adebamowo SN, et al. Comprehensive and integrated
genomic characterization of adult soft tissue sarcomas. *Cell*. 2017;171(4):950-965.

13. Wheeler DA, Roberts LR, Network CGAR. Comprehensive and integrative genomic
characterization of hepatocellular carcinoma. *Cell*. 2017;169(7):1327.

14. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers.
Nature. 2012;489(7417):519.

15. Levine DA. Integrated genomic characterization of endometrial carcinoma. *Nature*.
2013;497(7447):67-73.

16. Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of
gastric adenocarcinoma. *Nature*. 2014;513(7517):202.

17. Never-smoker NE smoker. Comprehensive molecular profiling of lung adenocarcinoma.
Nature. 2014;511:543-550.

18. Jendoubi T. Approaches to Integrating Metabolomics and Multi-Omics Data: A Primer.
Metabolites. 2021;11(3):184.

19. Clark C, Dayon L, Masoodi M, Bowman GL, Popp J. An integrative multi-omics approach
reveals new central nervous system pathway alterations in Alzheimer's disease. *Alzheimers*
Res Ther. 2021;13(1):1-19.

20. Nativio R, Lan Y, Donahue G, et al. An integrated multi-omics approach identifies epigenetic
alterations associated with Alzheimer's disease. *Nat Genet*. 2020;52(10):1024-1035.

21. Hampel H, Nisticò R, Seyfried NT, et al. Omics sciences for systems biology in Alzheimer's
disease: State-of-the-art of the evidence. *Ageing Res Rev*. 2021;69:101346.

22. Byrns CN, Bonini NM. An Integrated Multi-omics Approach Identifies Therapeutic Potential
for ATP6V1A in Late Onset Alzheimer's Disease. *Neuron*. 2021;109(2):193-194.

23. Sancesario GM, Bernardini S. Alzheimer's disease in the omics era. *Clin Biochem*.
2018;59:9-16.

24. Jin T, Rehani P, Ying M, et al. scGRNom: a computational pipeline of integrative multi-omics
analyses for predicting cell-type disease genes and regulatory networks. *Genome Med*.
2021;13(1):1-15.

25. Li Z, Jiang X, Wang Y, Kim Y. Applied machine learning in Alzheimer's disease research:
omics, imaging, and clinical data. *Emerg Top Life Sci*. 2021;5(6):765-777.

26. Canchi S, Raao B, Masliah D, et al. Integrating gene and protein expression reveals
perturbed functional networks in Alzheimer's disease. *Cell Rep*. 2019;28(4):1103-1116.

27. Xie L, He B, Varathan P, et al. Integrative-omics for discovery of network-level disease
biomarkers: a case study in Alzheimer's disease. *Brief Bioinform*. 2021;22(6):bbab121.

28. Ying M, Rehani P, Roussos P, Wang D. Integrative multi-omics analyses identify cell-type
disease genes and regulatory networks across schizophrenia and Alzheimer's disease.

29. Dube U, Del-Aguila JL, Li Z, et al. An atlas of cortical circular RNA expression in Alzheimer
disease brains demonstrates clinical and pathological associations. *Nat Neurosci*.
2019;22(11):1903-1912.

30. Chen HH, Eteleeb A, Wang C, et al. Circular RNA detection identifies circPSEN1 alterations
in brain specific to autosomal dominant Alzheimer's disease. *Acta Neuropathol Commun*.
2022;10(1):1-11.

31. Li Z, Del-Aguila JL, Dube U, et al. Genetic variants associated with Alzheimer's disease
confer different cerebral cortex cell-type population structure. *Genome Med*. 2018;10(1):1-
19.

32. Yang C, Farias FH, Ibanez L, et al. Genomic atlas of the proteome from brain, CSF and
plasma prioritizes proteins implicated in neurological disorders. *Nat Neurosci*.
2021;24(9):1302-1312.

33. Novotny BC, Fernandez MV, Wang C, et al. Metabolomic and lipidomic signatures in
autosomal dominant and late-onset Alzheimer's disease brains. *Alzheimers Dement J*
Alzheimers Assoc. Published online October 17, 2022. doi:10.1002/alz.12800

34. Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. *Biostatistics*. 2018;19(1):71-86.

35. Wang M, Beckmann ND, Roussos P, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. *Sci Data*. 2018;5(1):1-16.

36. A Bennett D, A Schneider J, Arvanitakis Z, S Wilson R. Overview and findings from the religious orders study. *Curr Alzheimer Res*. 2012;9(6):628-645.

37. Koopmans F, van Nierop P, Andres-Alonso M, et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. *Neuron*. 2019;103(2):217-234.

38. Zhu F, Cizeron M, Qiu Z, et al. Architecture of the mouse brain synaptome. *Neuron*. 2018;99(4):781-799.

39. Patel KR, Zhu K, Henrion MY, et al. Single cell-type integrative network modeling identified novel microglial-specific targets for the phagosome in Alzheimer's disease. *bioRxiv*. Published online 2020.

40. Wang X, Huang T, Bu G, Xu H. Dysregulation of protein trafficking in neurodegeneration. *Mol Neurodegener*. 2014;9(1):1-9.

41. Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L. Targeting the mTOR signaling network for Alzheimer's disease therapy. *Mol Neurobiol*. 2014;49(1):120-135.

42. Hwang J, Estick CM, Ikonne US, et al. The role of lysosomes in a broad disease-modifying approach evaluated across transgenic mouse models of Alzheimer's disease and Parkinson's disease and models of mild cognitive impairment. *Int J Mol Sci*. 2019;20(18):4432.

43. Butler D, Hwang J, Estick C, et al. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. *PloS One*. 2011;6(6):e20501.

44. Zhang L, Sheng R, Qin Z. The lysosome and neurodegenerative diseases. *Acta Biochim Biophys Sin*. 2009;41(6):437-445.

45. Root J, Merino P, Nuckols A, Johnson M, Kukar T. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. *Neurobiol Dis*. 2021;154:105360.

46. Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res Ther*. 2013;5(5):1-9.

47. Eshraghi M, Adlimoghaddam A, Mahmoodzadeh A, et al. Alzheimer's disease pathogenesis: Role of autophagy and mitophagy focusing in microglia. *Int J Mol Sci*. 2021;22(7):3330.

48. Li Q, Liu Y, Sun M. Autophagy and Alzheimer's disease. *Cell Mol Neurobiol*. 2017;37(3):377-388.

49. Zare-Shahabadi A, Masliah E, Johnson GV, Rezaei N. Autophagy in Alzheimer's disease. *Rev Neurosci*. 2015;26(4):385-395.

50. Nixon RA. The role of autophagy in neurodegenerative disease. *Nat Med*. 2013;19(8):983-997.

51. Funderburk SF, Marcellino BK, Yue Z. Cell "self-eating"(autophagy) mechanism in Alzheimer's disease. *Mt Sinai J Med J Transl Pers Med J Transl Pers Med*. 2010;77(1):59-68.

52. Dobson CB, Itzhaki RF. Herpes simplex virus type 1 and Alzheimer's disease. *Neurobiol Aging*. 1999;20(4):457-465.

53. Itzhaki RF. Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus. *Front Aging Neurosci*. 2014;6:202.

54. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. *J Pathol J Pathol Soc G B Irel*. 2009;217(1):131-138.

55. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *The Lancet*. 1997;349(9047):241-244.

56. Cairns DM, Rouleau N, Parker RN, Walsh KG, Gehrke L, Kaplan DL. A 3D human brain–like tissue model of herpes-induced Alzheimer's disease. *Sci Adv*. 2020;6(19):eaay8828.

57. Duarte LF, Farías MA, Álvarez DM, Bueno SM, Riedel CA, González PA. Herpes simplex virus type 1 infection of the central nervous system: insights into proposed interrelationships with neurodegenerative disorders. *Front Cell Neurosci*. 2019;13:46.

58. Ovsepian SV, O'Leary VB, Zaborszky L, Ntziachristos V, Dolly JO. Synaptic vesicle cycle and amyloid β: Biting the hand that feeds. *Alzheimers Dement*. 2018;14(4):502-513.

59. Greber S, Lubec G, Cairns N, Fountoulakis M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. *Electrophor Int J*. 1999;20(4-5):928-934.

60. Brinkmalm A, Brinkmalm G, Honer WG, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. *Mol Neurodegener*. 2014;9(1):1-13.

61. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. *Nat Rev Neurol*. Published online 2022:1-15.

62. Vranová HP, Hényková E, Mareš J, et al. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. *J Neurol Sci*. 2016;361:117-121.

63. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet*. 2009;41(10):1088-1093.

64. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at
CLU and CR1 associated with Alzheimer's disease. *Nat Genet*. 2009;41(10):1094-1099.

65. Moon HJ, Herring SK, Zhao L. Clusterin: a multifaceted protein in the brain. *Neural Regen*
Res. 2021;16(7):1438.

66. Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer's
disease: mechanisms, genetics, and lessons from other pathologies. *Front Neurosci*.
2019;13:164.

67. McCormick DA. GABA as an inhibitory neurotransmitter in human cerebral cortex. *J*
Neurophysiol. 1989;62(5):1018-1027.

68. Jiménez-Balado J, Eich TS. GABAergic dysfunction, neural network hyperactivity and
memory impairments in human aging and Alzheimer's disease. In: *Seminars in Cell &*
Developmental Biology. Elsevier; 2021.

69. Pillsbury L, Oria M, Erdman J. Nutrition and traumatic brain injury: improving acute and
subacute health outcomes in military personnel. Published online 2011.

70. Platten M, Nollen EA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a
common therapeutic target in cancer, neurodegeneration and beyond. *Nat Rev Drug Discov*.
2019;18(5):379-401.

71. Yan X, Hu Y, Wang B, Wang S, Zhang X. Metabolic dysregulation contributes to the
progression of Alzheimer's disease. *Front Neurosci*. 2020;14:1107.

72. An Y, Varma VR, Varma S, et al. Evidence for brain glucose dysregulation in Alzheimer's
disease. *Alzheimers Dement*. 2018;14(3):318-329.

73. Wang X, He HJ, Xiong X, et al. NAD+ in Alzheimer's Disease: Molecular Mechanisms and
Systematic Therapeutic Evidence Obtained in vivo. *Front Cell Dev Biol*. 2021;9:668491.

74. González A, Calfío C, Churruca M, Maccioni RB. Glucose metabolism and AD: evidence for
a potential diabetes type 3. *Alzheimers Res Ther*. 2022;14(1):1-11.

75. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in
Alzheimer's disease. *Neurobiol Aging*. 2010;31(3):398-408.

76. Vickland H, Silver J. The role of astrocytes in axon guidance during development and repair.
Glial Cell Dev Basic Princ Clin Relev Jessen KR Richardson WD Eds. Published online
1996:197-208.

77. Cheng J, Wang S, Dong Y, Yuan Z. The role and regulatory mechanism of hippo signaling
components in the neuronal system. *Front Immunol*. 2020;11:281.

78. Südhof TC. The synaptic vesicle cycle. *Annu Rev Neurosci*. 2004;27:509-547.

79. Chanaday NL, Cousin MA, Milosevic I, Watanabe S, Morgan JR. The synaptic vesicle cycle
revisited: new insights into the modes and mechanisms. *J Neurosci*. 2019;39(42):8209-
8216.

80. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. *Neuron*. 2012;76(1):70-81.

81. Dong A, Liu S, Li Y. Gap junctions in the nervous system: probing functional connections using new imaging approaches. *Front Cell Neurosci*. 2018;12:320.

82. Blue EE, Thornton TA, Kooperberg C, et al. Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women. *Alzheimers Dement*. 2021;17(2):215-225.

83. Ou YN, Yang YX, Deng YT, et al. Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood. *Mol Psychiatry*. Published online 2021:1-9.

84. Carnazza KE, Komer LE, Xie YX, et al. Synaptic vesicle binding of α-synuclein is modulated by β-and γ-synucleins. *Cell Rep*. 2022;39(2):110675.

85. Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha-synuclein. *Mol Neurobiol*. 2004;30(1):1-21. doi:10.1385/MN:30:1:001

86. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. *J Neurosci Off J Soc Neurosci*. 2005;25(25):6016-6024. doi:10.1523/JNEUROSCI.0692-05.2005

87. Yamada K, Iwatsubo T. Extracellular α-synuclein levels are regulated by neuronal activity. *Mol Neurodegener*. 2018;13(1):1-8.

88. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science*. 1997;276(5321):2045-2047. doi:10.1126/science.276.5321.2045

89. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-840. doi:10.1038/42166

90. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. *Science*. 2000;287(5456):1265-1269. doi:10.1126/science.287.5456.1265

91. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. *Science*. 2003;302(5646):841. doi:10.1126/science.1090278

92. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. *Neuron*. 2002;34(4):521-533. doi:10.1016/s0896-6273(02)00682-7

93. Lee MK, Stirling W, Xu Y, et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53→ Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. *Proc Natl Acad Sci*. 2002;99(13):8968-8973.

94. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science*. 2012;338(6109):949-953. doi:10.1126/science.1227157

95. Davis AA, Inman CE, Wargel ZM, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. *Sci Transl Med*. 2020;12(529):eaay3069.

96. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. *J Neuropathol Exp Neurol*. 2003;62(4):363-367.

97. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am J Pathol*. 1998;153(5):1365-1370.

98. Lippa CF, Schmidt ML, Lee VMY, Trojanowski JQ. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. *Ann Neurol Off J Am Neurol Assoc Child Neurol Soc*. 1999;45(3):353-357.

99. Sekiya M, Wang M, Fujisaki N, et al. Integrated biology approach reveals molecular and pathological interactions among Alzheimer's Aβ42, Tau, TREM2, and TYROBP in Drosophila models. *Genome Med*. 2018;10(1):1-20.

100. Iacono D, Resnick SM, O'Brien R, et al. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. *J Neuropathol Exp Neurol*. 2014;73(4):295-304.

101. Martorana A, Koch G. Is dopamine involved in Alzheimer's disease? *Front Aging Neurosci*. 2014;6:252.

102. Koch G, Di Lorenzo F, Bonnì S, et al. Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients. *Neuropsychopharmacology*. 2014;39(11):2654-2661.

103. Nobili A, Latagliata EC, Viscomi MT, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. *Nat Commun*. 2017;8(1):1-14.

104. Cordella A, Krashia P, Nobili A, et al. Dopamine loss alters the hippocampus-nucleus accumbens synaptic transmission in the Tg2576 mouse model of Alzheimer's disease. *Neurobiol Dis*. 2018;116:142-154.

105. Ceyzériat K, Gloria Y, Tsartsalis S, et al. Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer's disease. *Brain Commun*. 2021;3(2):fcab029.

106. Koch G, Esposito Z, Codecà C, et al. Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. *Clin Neurophysiol*. 2011;122(4):703-707.

107. Guzmán-Ramos K, Moreno-Castilla P, Castro-Cruz M, et al. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. *Learn Mem*. 2012;19(10):453-460.

108. Perez SE, Lazarov O, Koprich JB, et al. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1ΔE9 transgenic mice. *J Neurosci*. 2005;25(44):10220-10229.

109. Ambrée O, Richter H, Sachser N, et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. *Neurobiol Aging*. 2009;30(8):1192-1204.

110. Bukke VN, Archana M, Villani R, et al. The dual role of glutamatergic neurotransmission in Alzheimer's disease: from pathophysiology to pharmacotherapy. *Int J Mol Sci*. 2020;21(20):7452.

111. Conway ME. Alzheimer's disease: targeting the glutamatergic system. *Biogerontology*. 2020;21(3):257-274.

112. Rodriguez-Perdigon M, Tordera RM, Gil-Bea FJ, Gerenu G, Ramirez MJ, Solas M. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease. *Hippocampus*. 2016;26(10):1303-1312.

113. Cheng YJ, Lin CH, Lane HY. Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer's disease. *Int J Mol Sci*. 2021;22(5):2283.

114. Colangelo AM, Alberghina L, Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. *Neurosci Lett*. 2014;565:59-64.

115. Abu-Rumeileh S, Steinacker P, Polischi B, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. *Alzheimers Res Ther*. 2020;12(1):1-15.

116. Ishiki A, Kamada M, Kawamura Y, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. *J Neurochem*. 2016;136(2):258-261.

117. Jesse S, Steinacker P, Cepek L, et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. *J Alzheimers Dis*. 2009;17(3):541-551.

118. Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment. *J Alzheimers Dis*. 2019;67(2):481-488.

119. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. *Dement Geriatr Cogn Disord*. 1996;7(5):267-272.

120. Cicognola C, Janelidze S, Hertze J, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. *Alzheimers Res Ther*. 2021;13(1):1-9.

121. Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Transl Psychiatry*. 2021;11(1):1-10.

122. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress
Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in
vivo. *Neuron*. 2004;41(2):193-202.

123. Zandl-Lang M, Fanaee-Danesh E, Sun Y, et al. Regulatory effects of simvastatin and apoJ
on APP processing and amyloid-β clearance in blood-brain barrier endothelial cells.
Biochim Biophys Acta BBA-Mol Cell Biol Lipids. 2018;1863(1):40-60.

124. Nuutinen T, Huuskonen J, Suuronen T, Ojala J, Miettinen R, Salminen A. Amyloid-β 1–42
induced endocytosis and clusterin/apoJ protein accumulation in cultured human
astrocytes. *Neurochem Int*. 2007;50(3):540-547.

125. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins,
including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by
microglia. *Neuron*. 2016;91(2):328-340.

126. Robbins JP, Perfect L, Ribe EM, et al. Clusterin is required for β-amyloid toxicity in human
iPSC-derived neurons. *Front Neurosci*. 2018;12:504.

127. Killick R, Ribe EM, Al-Shawi R, et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-
driven induction of the wnt–PCP–JNK pathway. *Mol Psychiatry*. 2014;19(1):88-98.

128. Sobue A, Komine O, Hara Y, et al. Microglial gene signature reveals loss of homeostatic
microglia associated with neurodegeneration of Alzheimer's disease. *Acta Neuropathol*
Commun. 2021;9(1):1-17.

129. Puntambekar SS, Moutinho M, Lin PBC, et al. CX3CR1 deficiency aggravates amyloid
driven neuronal pathology and cognitive decline in Alzheimer's disease. *Mol*
Neurodegener. 2022;17(1):47. doi:10.1186/s13024-022-00545-9

130. Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C. The Consortium to
Establish a Registry for Alzheimer's Disease (CERAD): Part IX. A prospective
cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. *Neurology*.
1995;45(11):1991-1995.

131. Hansen LA. The Lewy body variant of Alzheimer disease. In: *Dementia in Parkinsonism*.
Springer; 1997:83-93.

132. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145
cases using α-synuclein immunohistochemistry. *Brain Pathol*. 2000;10(3):378-384.

133. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. α-Synuclein-positive
structures in cases with sporadic Alzheimer's disease: morphology and its relationship to
tau aggregation. *Brain Res*. 2001;888(2):287-296.

134. Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in
two multi-center longitudinal observational studies: The A lzheimer D isease N
euroimaging I nitiative (ADNI) and the D ominantly I nherited A lzheimer N etwork (DIAN).
Neuropathology. 2015;35(4):390-400.

135. Bassil F, Brown HJ, Pattabhiraman S, et al. Amyloid-beta (Aβ) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with Aβ pathology. *Neuron*. 2020;105(2):260-275.

136. Bassil F, Meymand ES, Brown HJ, et al. α-Synuclein modulates tau spreading in mouse brains. *J Exp Med*. 2021;218(1).

137. Henderson MX, Trojanowski JQ, Lee VMY. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. *Neurosci Lett*. 2019;709:134316.

138. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. *Neuron*. 2011;72(1):57-71.

139. Wu Q, Shaikh MA, Meymand ES, et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. *Acta Neuropathol (Berl)*. 2020;140(6):831-849.

140. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of α-synuclein. *J Neurosci*. 2005;25(47):10913-10921.

141. Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. *Nat Preced*. Published online 2010:1-1.

142. Del-Aguila JL, Li Z, Dube U, et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimers Res Ther*. 2019;11(1):1-16.

143. Brase L, You SF, Del-Aguila JL, et al. A landscape of the genetic and cellular heterogeneity in Alzheimer disease. *medRxiv*. Published online 2021.

144. Johnson EC, Carter EK, Dammer EB, et al. Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. *Nat Neurosci*. 2022;25(2):213-225.

145. Bai B, Wang X, Li Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression. *Neuron*. 2020;105(6):975-991.

146. Arnold M, Nho K, Kueider-Paisley A, et al. Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome. *Nat Commun*. 2020;11(1):1-12.

147. Toledo JB, Arnold M, Kastenmueller G, et al. Metabolic network failures in Alzheimer's disease: a biochemical road map. *Alzheimers Dement*. 2017;13(9):965-984.

148. John-Williams S, Blach C, Toledo JB, et al. Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. *Sci Data*. 2017;4(1):1-11.

149. Batra R, Arnold M, Wörheide MA, et al. The landscape of metabolic brain alterations in Alzheimer's disease. *bioRxiv*. Published online 2021.

150. Andrews S. FastQC: a quality control tool for high throughput sequence data. Published
online 2010.

151. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner.
Bioinformatics. 2013;29(1):15-21.

152. Picard Toolkit." 2019. Broad Institute, GitHub Repository.
https://broadinstitute.github.io/picard/; Broad Institute.

153. Novotny BC, Fernandez MV, Bahena J, et al. Metabolomic and lipidomic signatures in
autosomal dominant and late-onset Alzheimer disease brains. *medRxiv*. Published online
2021.

154. Lê S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. *J Stat
Softw*. 2008;25:1-18.

155. Hastie T, Tibshirani R, Narasimhan B, Chu G. impute: impute: Imputation for microarray
data. Published online 2018.

156. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing
batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics*.
2012;28(6):882-883.

157. Zheng GX, Terry JM, Belgrader P, et al. Massively parallel digital transcriptional profiling of
single cells. *Nat Commun*. 2017;8(1):1-12.

158. Mo Q, Shen R. iClusterPlus: integrative clustering of multiple genomic data sets.
Published online 2013.

159. Gaujoux R, Seoighe C. CellMix: a comprehensive toolbox for gene expression
deconvolution. *Bioinformatics*. 2013;29(17):2211-2212.

160. Gaujoux R, Seoighe C. Semi-supervised Nonnegative Matrix Factorization for gene
expression deconvolution: a case study. *Infect Genet Evol*. 2012;12(5):913-921.

161. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):1-21.

162. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
approach to multiple testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289-300.

163. Therneau T. A Package for Survival Analysis in R. R package version 3.2-3. Published
online 2020. https://CRAN.R-project.org/package=survival

164. Eklund A. surviplot: Draw Survival Curves with Number-at-Risk. R package version 1.1.1.
Published online 2017. http://www.cbs.dtu.dk/~eklund/surviplot/

165. Team RDC. R: A language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. *URL Httpwww Rproject Org*. Published online
2008.

166. Jawaid W. enrichR: Provides an R Interface to "Enrichr". R package version 3.0. https://CRAN.R-project.org/package=enrichR. Published online 2021.

167. Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. *Nucleic Acids Res*. 2021;49(W1):W388-W396.

Acknowledgements

We thank all the participants and their families, as well as the many involved institutions and their staff, whose help and participation made this work possible. Research reported in this work was supported by the Knight Alzheimer Disease Research Center at Washington University School of Medicine through the National Institute on Aging (NIA: grant no. P30 AG066444 - JCM), Healthy Aging and Senile Dementia (HASD: grant no. P01AG003991 - JCM), and Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study (ACS: grant no. P01AG026276 - JCM). This work was supported by grants from the National Institutes of Health: NIA R01AG057777 (OH), K01AG046374 (CMK), R56AG067764 (OH), the Chan Zuckerberg Initiative (CMK). O.H. is an Archer Foundation Research Scientist. A.M.E. is a scholar recipient of the Knight ADRC Research Education Component (NIA: grant no. P30 AG066444). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

ROSMAP (RNA-seq)

Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu. Study data were provided through NIA grant 3R01AG046171-02S2 awarded to Rima Kaddurah-Daouk at Duke University, based on specimens provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, where

data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute.

Alzheimer's Disease Metabolomics Consortium (ADMC)

The results published here are in whole or partly based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). Metabolomics data is provided by the Alzheimer's Disease Metabolomics Consortium (ADMC) and funded wholly or in part by the following grants and supplements: NIA R01AG046171, RF1AG051550, 3U01AG024904-09S4, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744, and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the ADMC, not listed specifically in this publication's author's list, provided data along with its pre-processing and prepared it for analysis but did not participate in the analysis or writing of this manuscript. A complete listing of ADMC investigators can be found at: https://sites.duke.edu/adnimetab/team/.

MSBB

The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). These data were generated from postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank and were provided by Dr. Eric Schadt from Mount Sinai School of Medicine. Proteomics data were provided by Dr. Levey from Emory University based on postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank provided by Dr. Eric Schadt from Mount Sinai School of Medicine.

Competing interests

The authors declare no competing interests.

Supplementary information

Supplementary Figures 1-19

Supplementary Tables 1–9

1384   **Tables**

1385

1386   **Table 1**: **Demographic characteristics of AD and control subjects.**

Study	N	Tissue[a]	Data[b]	AD			Control		
				Female (%)	Age (mean,sd)	APOE Ɛ4+ (%)	Female (%)	Age (mean,sd)	APOE Ɛ4+ (%)
Knight ADRC	278	PC	T,P,M	60	83.8(8.6)	58.04	73.9	88.6(8.8)	0
MSBB	217	BM36	T,P	67.1	84.4(6.7)	19.29	66.6	80.6(8.3)	18.5
		BM10	T	67.0	84.2(6.8)	20.73	69.7	81.3(7.0)	15.1
		BM22	T	62.9	83.6(6.9)	23.38	70	81(8.0)	16.6
		BM44	T	66.6	84.3(6.7)	20.92	64.2	80.5(8.3)	17.8
ROSMAP	237	DLPFC	T,M	70.8	90.7(5.9)	39.58	53.7	84.1(6.8)	10.7

1387   [a]PC (parietal cortex), BM10 (frontal pole), BM22 (superior temporal gyrus), BM44 (inferior frontal gyrus), DLPFC
1388   (dorsolateral prefrontal cortex).
1389   [b]Data availability, T, transcriptomics; P, proteomics; M, metabolomics.

1390 **Table 2: Summary of the significant features detected between each cluster and the**

1391 **control.**

Cluster	RNA-seq			Proteomics			Metabolomics		
	Total	Specific[a]	Missed[b]	Total	Specific	Missed	Total	Specific	Missed
1	385	67 (17%)	108 (28%)	71	24 (34%)	59(83%)	0	0(0%)	0(0%)
2	560	102 (18%)	312 (56%)	456	232 (51%)	448 (98%)	1	1(100%)	1(100%)
3	356	36 (10%)	137 (38%)	4	0 (0%)	1(25%)	0	0(0%)	0(0%)
4	4661	4210 (90%)	4295 (92%)	485	250 (52%)	475(98%)	90	90(100%)	90(100%)

1392   [a] features detected only in the specific cluster.
1393   [b] indicates the number and percentage of features missed when un-clustered AD cases were compared to the
1394   control.

1395 **Table 3: Number of significant features between each cluster and the other clusters.**

Cluster	Transcriptomics	Proteomics	Metabolomics
1	678	499	105
2	22	683	0
3	1	413	0
4	6822	562	228

1396

1397 **Table 4: Number and percentage of significant features specific to each cell type.**

Cell-type	Upregulated				Downregulated			
	C1	C2	C3	C4	C1	C2	C3	C4
Astrocyte	0(0%)	1(3%)	0(0%)	214(38%)	6(40%)	21 (75%)	5(38%)	11 (3%)
Microglia	3(19%)	5(14%)	0(0%)	56(10%)	1(7%)	1 (4%)	2(15%)	112 (31%)
Neuron	3(19%)	2(6%)	2(22%)	25(4%)	1(7%)	1 (4%)	0 (0%)	108 (30%)
Oligodendrocyte	3(19%)	21(60%)	5(56%)	85(15%)	0(0%)	1 (4%)	0 (0%)	77 (21%)
OPC	0(0%)	3(9%)	1(11%)	50(9%)	6(40%)	2 (7%)	1(8%)	48 (13%)
Endothelial	7(44%)	3(9%)	1(11%)	130(23%)	1(7%)	2 (7%)	5(38%)	8 (2%)

1398

Figure Legends

Fig. 1: Study design. The transcriptomics, proteomics, metabolomics and lipidomics profiles of postmortem parietal cortex samples from the Knight ADRC participants were used. 278 subjects (255 sporadic AD and 23 control cases) were shared across the three omics. Expression/reading matrices were prepared for the same set of samples (n=278) and different number of features (genes=60,754, proteins=1,092, metabolites=627). Prior to the integration, feature selection was performed on all omics datasets whose number of features exceeded 1000 features by selecting the top most variant features. A Bayesian integrative clustering method (iClusterBayes) was then employed to integrate the three omics datasets and the best clustering solution was extracted based on the maximum deviance ratio and the minimum Bayesian information criterion (BIC). AD molecular profiles were then linked to multiple clinical and molecular attributes to examine whether an association with these attributes exists. In addition, multiple analyses including survival, differential expression, cell-type specific effect, and cell proportions inference analyses were performed on these profiles. These molecular profiles were then replicated in two independent datasets from MSBB BM36 (AD=93, CO=23) and ROSMAP (AD=144, CO=93).

Fig. 2: Cross-omics data integration identified four distinct molecular profiles of AD associated with worse clinical outcomes and molecular attributes. (a) Heatmaps of multi-omics profiles of the top significant features. **(b)** Transcriptomic profiles **(**scaled) of the top genes that contributed significantly to the clustering, showing an overall dysregulation of brains in Knight-C4. (**c**) The distribution of CDR scores across four clusters with Knight-C4 associated with high CDR scores. (**d**) Kaplan-Meier plots showing Knight-C4 association with poor outcome for age of onset and age of death. (**e**) Boxplots showing the cell proportion from deconvolution analysis across four clusters using bulk RNA-seq from four cell types. Knight-C4 is associated with significantly higher and lower proportion of astrocytes and neurons respectively. (**f**) Boxplot showing the first principal component of metabolomics profiles for each cluster with Knight-C2 and Knight-C4 showing a lower metabolomic signature than other AD cases.

Fig. 3: Molecular profiles of Knight-C4 are replicated in two independent datasets. (**a**) Heatmaps of the transcriptomic and proteomic profiles of the top features from MSBB (BM36) showing two distinct clusters. (**b**) Boxplots showing MSBB-C1 associated with higher CDR scores, replicating Knight-C4 in the knight ADRC. (**c**) Boxplots showing cell proportions inferred from bulk RNA-seq from MSBB (BM36) using digital deconvolution. MSBB-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons

respectively. (**d**) Heatmap of the transcriptomic profiles of the top features from ROSMAP (DLPFC) showing two distinct clusters. (**e**) Boxplots showing ROSMAP-C1 associated with lower MMSE30 scores. (**f**) Boxplots showing cell proportion estimated from bulk RNA-seq from ROSMAP (DLPFC) using digital deconvolution. Similar to MSBB, ROSMAP-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons respectively.

Fig. 4: The parietal cortex of subjects with worse cognitive function exhibited a remarkable molecular dysregulation. (**a**) Bar plots showing the significant genes detected in each cluster when compared to the control. Yellow color represents the total number of genes, green represents the cluster-specific genes, and the purple depicts the number of genes missed with un-clustered approach (all AD cases vs control). (**b**) Same as panel "a" but for proteins. (**c**) Same as panel "a" but for metabolites. (**d**) Race track plot showing the percentage of significant features for each cluster when compared to other clusters for the three omics. (**e**) Venn diagrams showing the overlap between significant genes in Knight-C4 and synaptic genes from Fei *et al.,* 2018[38]. (**f**) Same as "e" but overlapped with SynGO dataset[37]. The significance of overlap was computed using Fisher's exact test. (**g**) Top 20 KEGG pathways associated with Knight-C4. (**h**) Top 20 GO biological process pathways associated with Knight-C4.

Fig. 5: Differential expression analyses identified neurodegenerative disease genes associated with distinct clusters. (**a**) Volcano plot showing the up-and downregulated genes identified between Knight-C4 vs other clusters. Genes in red are examples of known neurodegenerative disease genes. Genes in black are the top 10 significant genes based on the adjusted p-value and genes with log2(fold change) > 1. (**b**) Boxplots showing the transcriptomic profiles (in FPKM) of *SNAP25* across four clusters (right) and for AD cases combined (left) in the Knight ADRC cohort. (**c**) Same as "b" but for *GFAP*. (**d**) Volcano plot showing the up-and downregulated proteins identified between Knight-C2 vs other clusters. (**e**) Boxplots showing the proteomic profiles of *CLU* across four clusters (right) and for all AD cases (left) in the Knight ADRC cohort. (**f**) Kaplan-Meier plot showing the association of *CLU* downregulation with an increased risk of dementia progression using CDR change over time using CSF dataset from the Knight ADRC participants.

Fig. 6: Differential abundance analyses identified significant metabolites and pathways associated with Knight-C4. (**a**) Venn diagrams showing the significant increased and decreased

1468   metabolites shared between the Knight-C4 and ROSMAP-C1 when compared to the control. Left

1469   and right boxes show the names of shared metabolites. (**b**) Similar to panel "a" but for metabolites

1470   shared between Knight-C4 and ROSMAP-C1 when compared to the other cases. The significant

1471   of overlap was computed using Fisher's exact test.

1472

Fig. 7: The integration of single-nuclei data with cross-omics profiles identified cell-type

specific genes and pathways. (**a**) Bar plots showing the percentage of up-and downregulated

genes (clusters vs control) identified in each cell type. (**b**) Top 20 KEGG pathways enriched in

astrocytic upregulated genes. (**c**) Top 20 GO biological process pathways enriched in neuronal

downregulated genes. (**d**) Top KEGG pathways enriched in neuronal downregulated genes. (**e**)

Boxplots showing the transcriptomic profiles (in FPKM) of examples of cell-type specific genes

identified in the Knight ADRC cohort. (**f**) The effect size of these examples generated from single-

nuclei data from the Knight ADRC participants. Red bars represent the cell type in which the gene

is overexpressed.

1482

Fig. 8: Cross-omics integration identified alpha-synuclein levels downregulated in AD

participants with worse cognitive function common across multiple brain regions. (**a**)

Transcriptomic profiles (in FPKM) of *SNCA* across four clusters (right) and for all AD cases (left)

in the Knight ADRC cohort. (**b**) Proteomic profiles of *SNCA* across four clusters (right) and all AD

cases (left) in Knight ADRC cohort. (**c**) Transcriptomic profiles of *SNCA* across four clusters (right)

and all AD cases (left) in MSBB BM36 cohort. (**d**) Proteomic (TMT) profiles of *SNCA* across four

clusters (right) and all AD cases (left) in MSBB BM36 cohort. (**e**) Transcriptomic profiles of *SNCA*

across four clusters (right) and all AD cases (left) in ROSMAP DLPFC cohort.

1491

    Supplementary Figures

    Supplementary Fig. 1: The maximum deviance ratio (left) and the minimum Bayesian
    information criterion—BIC (right) results across cluster solutions. The optimal solution is
    observed with cluster number *K=3* dividing our samples into four clusters (*k+1*).

    Supplementary Fig. 2: Knight-C4 is not associated with polygenic risk scores (PRS).
    Boxplots showing the polygenic risk scores (PRS) across four clusters using four different p-value
    thresholds showing no significant association between Knight-C4 and PRS scores.

    Supplementary Fig. 3: Knight-C4 is not associated with genetic or neuropathological
    effects. (**a**) The distribution of APOE Ɛ4 allele across four clusters showing no association with
    Knight-C4. (**b**) The distribution of Braak scores for tau across four clusters showing no significant
    correlation between Knight-C4 and Braak staging for tau. However, Knight-C4 exhibited more 6
    stage cases exceeding the mean distribution of Braak stage 6 (dashed line) across all clusters.
    (**d**) The distribution of Braak scores for amyloid-β across four clusters showing no association
    with Knight-C4.

    Supplementary Fig. 4: Dysregulated genes are significantly common across cohorts from
    multiple brain regions. (**a**) Venn diagrams depicting the overlap between significant genes in
    Knight-C4 and MSBB-C1 cohorts, showing a replication of the molecular signature with worse
    cognitive outcomes. (**b**) Same as "a" but for significant proteins. (**c**) Venn diagrams depicting the
    overlap between significant genes in Knight-C4 and ROSMAP-C1 cohorts, showing a replication
    of the molecular signature with worse cognitive outcomes.

    Supplementary Fig. 5: Molecular profiles of MSBB-C1 are associated with high Braak
    scores for tau and replicated in additional brain regions from MSBB study. (**a**) Boxplots
    showing MSBB-C1 is associated with high BraakTau scores. (**b**) Boxplots showing a clear pattern
    of an association with early age of death for cases in MSBB-C1. (**c**) Heatmaps showing the
    replication of transcriptomic profiles of MSBB-C1 from BM36 region in additional regions including
    frontal pole (BM10), superior temporal gyrus (BM22), and inferior frontal gyrus (BM44) brain
    regions from MSBB study.

1525

Supplementary Fig. 6: Molecular profiles of ROSMAP-C1 are associated with multiple neuropathological variables. (a) Boxplots showing ROSMAP-C1 association with high tangle densities. (**b**) Boxplots showing ROSMAP-C1 association with neurofibrillary tangle burdens. (**c**) Boxplots showing higher plaque densities for AD cases in ROSMAP-C1.

1530

Supplementary Fig. 7: Knight-C4 is associated with higher number of significant hits across multi-omics datasets. (**a**) Venn diagrams showing the number of differentially expressed genes detected in each cluster (cluster vs control). (**b**) Same as panel "a" but for proteomics. (**c**) Same as panel "a" but for metabolomics.

1535

Supplementary Fig. 8: Significant enrichment of dysregulated synaptic genes in Knight-C4 is replicated in additional brain regions. (**a**) Venn Diagrams showing the overlap between significant genes in MSBB-C1 and synaptic genes from Fei *et al.,* 2018[38] and SynGO[37] datasets. (**b**) Same as "a" but overlapped with significant genes in ROSMAP-C1.

1540

Supplementary Fig. 9: Top significant pathways associated with Knight-C4 when brains are compared to the control. (**a**) Top 20 KEGG pathways enriched in Knight-C4 downregulated genes. (**b**) Top 20 GO biological process pathways enriched in Knight-C4 downregulated genes.

1544

Supplementary Fig. 10: Top significant pathways associated with Knight-C4 that are enriched in downregulated proteins. (**a**) Top 20 KEGG pathways associated with the downregulation of proteins in Knight-C4. (**b**) Top 20 GO biological process pathways enriched in Knight-C4 downregulated proteins.

1549

Supplementary Fig. 11: The decreased expression of *SNAP25* in Knight-C4 is replicated in MSBB and ROSMAP cohorts. (**a**) Boxplots showing transcriptomic profiles of *SNAP25* across the two clusters (right) and all ADs (left) in MSBB (BM36) cohort. (**b**) Boxplots showing proteomic (TMT) profiles of *SNAP25* across the two clusters as mentioned in "a". (**c**) Boxplots showing transcriptomic profiles of *SNAP25* across the two clusters (right) and all ADs (left) in ROSMAP (DLPFC) cohort.

1556

Supplementary Fig. 12: *GFAP* proteomic levels are dysregulated across distinct clusters. *GFAP* protomeric levels are significantly increased in Knight-C2 when compared to the control and other AD cases (right).

Supplementary Fig. 13: The increased level of *GFAP* is replicated in MSBB and ROSMAP datasets. (**a**) Boxplots showing the transcriptomic profiles of *GFAP* across the two clusters (right) and all AD cases (left) in MSBB (BM36) cohort. (**b**) Same as "a" but for the proteomic profiles (TMT). (**c**) Same as "a" but in ROSMAP (DLPFC) cohort.

Supplementary Fig. 14: Differential abundance and pathways analyses identified metabolites decreased in Knight-C4 and ROSMAP-C1. (a) Boxplots showing the decrease of metabolomics profiles of gamma-aminobutyrate (GABA) in Knight-C4 (left) and ROSMAP-C1 (right). (**b**) Same as "a" but for choline metabolite.

Supplementary Fig. 15: Differential abundance and pathway analyses identified metabolites increased in Knight-C4 and ROSMAP-C1. (**a**) Boxplots showing the increase of metabolomic profiles of tryptophan in Knight-C4 (left) and ROSMAP-C1 (right). (**b**) Same as "a" but for glucose metabolite.

Supplementary Fig. 16: Metabolic differential abundance and pathway analyses identified multiple dysregulated carbohydrate/sugar and sphingolipid metabolites. (a) Boxplots showing the decrease of metabolomic profiles of citrate in Knight-C4 (left) and ROSMAP-C1. (**b**) Boxplots showing the decrease of metabolomic profiles of NAD+ in both Knight-C4 (left) and ROSMAP-C1 (right). (**d**) Boxplots showing the increased metabolism levels of sphingosine in both Knight-C4 (left) and ROSMAP-C1 (right).

Supplementary Fig. 17: The integration of single-nuclei data with cross-omics profiles identified cell-type specific pathways. (a) Top 20 KEGG pathways enriched in endothelial upregulated genes (Knight-C4 vs Control). (**b**) Top 20 KEGG pathways enriched in microglia downregulated genes (Knight-C4 vs Control).

Supplementary Fig. 18: Downregulation of *SNCA* is replicated in additional brain regions from MSBB study. (**a**) Boxplot showing the transcriptomic profiles of *SNCA* in MSBB-C1 from

1590   frontal pole (BM10) brain region. (**b**) Same as "a" but from superior temporal gyrus (BM22). (**d**)

1591   Same as "a" and "b" but from inferior frontal gyrus (BM44) brain region from MSBB.

1592

1593   **Supplementary Fig. 19: The synaptic dysregulation in Knight-C4 is recapitulated in some**

1594   **degree in mouse models.** (**a**) Venn diagram showing the overlap between significant genes in

1595   Knight-C4 when compared to other clusters, significant genes from NanoString gene expression

1596   data from A53T αSyn mouse models, and synaptic genes from SynGO dataset. (b) Same as "a"

1597   but using significant genes in Knight-C4 when compared to the control.

Fig. 1

Fig. 2

Fig. 3

MSBB (BM36)

ROSMAP (DLPFC)

Fig. 4

Fig. 5

Fig. 6

a

KnightADRC: Knight-C4 vs Control
ROSMAP   : ROSMAP-C1 vs Control

Increased metabolites   Decreased metabolites

ROSMAP (148)   KnightADRC (101)   KnightADRC (51)   ROSMAP (42)

105   43   58   37   14   28

Fisher's pval < 2.2e–16

Left box (a):
1-(1-enyl-palmitoyl)-GPE (P-16:0)*
1-carboxyethylphenylalanine
1-methylnicotinamide
1-stearoyl-GPS (18:0)*
2'-AMP
2'-deoxyguanosine
2'-deoxyinosine
2R,3R-dihydroxybutyrate
3-hydroxypalmitoylcarnitine
5-methyluridine (ribothymidine)
6-oxopiperidine-2-carboxylate
arginine
creatinine
cysteinylglycine disulfide*
dehydroascorbate
dimethylarginine (ADMA + SDMA)
erythronate*
glucose
glycerophosphoethanolamine
glycerophosphorylcholine (GPC)
glycylvaline
inositol 1-phosphate (I1P)
mannitol/sorbitol
methionine sulfoxide
N-acetyl-glucosamine 1-phosphate
N-formylanthranilic acid
N-formylphenylalanine
N-monomethylarginine
N2,N2-dimethylguanosine
N6-acetyllysine
phenylalanine
phenylalanylglycine
ribose
saccharopine
sphingadienine
sphingosine
threonate
tryptophan
tyrosine
tyrosylglycine
UDP-glucose
urea

Right box (a):
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)*
arachidonoyl ethanolamine
betaine
choline
dihydroxyacetone phosphate (DHAP)
FAD
gamma-aminobutyrate (GABA)
homocarnosine
hypoxanthine
N-acetyl-3-methylhistidine*
NADHX*
phosphoethanolamine (PE)
trigonelline (N'-methylnicotinate)
uracil

b

KnightADRC: Knight-C4 vs Knight-C1-3
ROSMAP   : ROSMAP-C1 vs ROSMAP-C2

Increased metabolites   Decreased metabolites

ROSMAP (163)   KnightADRC (197)   KnightADRC (77)   ROSMAP (20)

93   70   127   73   4   16

Fisher's pval < 2.2e–16

Left box (b):
1-(1-enyl-palmitoyl)-GPE (P-16:0)*
1-carboxyethylisoleucine
1-carboxyethylleucine
1-carboxyethylphenylalanine
1-carboxyethyltyrosine
1-carboxyethylvaline
1-methyladenosine
1-methylnicotinamide
1-stearoyl-GPS (18:0)*
15-KETE
2-hydroxybutyrate/2-hydroxyisobutyrate
2'-AMP
2'-deoxyguanosine
2'-deoxyinosine
2S,3R-dihydroxybutyrate
3-formylindole
6-oxopiperidine-2-carboxylate
7-methylguanine
alanine
arginine
asparagine
carnitine
dehydroascorbate
dimethylarginine (ADMA + SDMA)
fructose
fructosyllysine
glucose
glycerate
glycerophosphoserine*
glycylvaline
inositol 1-phosphate (I1P)
isobutyrylcarnitine (C4)
isoleucine
lactate
leucine
lysine
mannitol/sorbitol
methionine
methionine sulfoxide
N-acetyl-glucosamine 1-phosphate
N-acetylalanine
N-acetylmethionine sulfoxide
N-formylanthranilic acid
N-formylphenylalanine
N-monomethylarginine
N1-methylinosine
N2,N2-dimethylguanosine
N6-acetyllysine
N6,N6,N6-trimethyllysine
palmitoyl sphingomyelin (d18:1/16:0)
phenylalanine
phenylalanylglycine
phytosphingosine
pyridoxamine
ribose
sedoheptulose
serine
spermidine
sphingadienine
sphingomyelin (d18:2/18:1)*
sphingosine
threonine
tryptophan
tyrosine
tyrosylglycine
UDP-glucose
uridine
valine
xanthine
xanthosine

Right box (b):
choline
citrate
gamma-aminobutyrate (GABA)
NAD+

Fig. 7

Fig. 8

Supplementary Fig. 1

Supplementary Fig. 2

Supplementary Fig. 3

Supplementary Fig. 4

a

MSBB (BM36)

Transcriptomics

MSBB-C1 (7251)   Knight-C4 (3621)

5321   1927   1694

Up-regulated

Fisher's pval < 2.2e-16

MSBB-C1 (6630)   Knight-C4 (3201)

4280   2348   853

Down-regulated

b

Proteomics

MSBB-C1 (570)   Knight-C4 (252)

553   17   235

Up-regulated

Fisher's pval = 6.8e-01

MSBB-C1 (666)   Knight-C4 (326)

656   10   316

Down-regulated

c

ROSMAP (DLPFC)

Transcriptomics

Knight-C4 (3621)   ROSMAP-C1 (2310)

2697   924   1386

Up-regulated
Fisher's pval = 2.5e−264

Fisher's pval < 2.2e-16

Knight-C4 (3201)   ROSMAP-C1 (2889)

1771   1430   1459

Down-regulated

Supplementary Fig. 5

Supplementary Fig. 6

a

Supplementary Fig. 8

a

b

Supplementary Fig. 9

a

Top KEGG pathways
Downregulated genes (Knight-C4 vs Control)

b

Top GO biological process pathways
Downregulated genes (Knight-C4 vs Control)

Supplementary Fig. 10

a

Top KEGG pathways
Downregulated proteins (Knight-C4 vs Control)

b

Top GO biological processe pathways
Downregulated proteins (Knight-C4 vs Control)

Supplementary Fig. 11

Supplementary Fig. 12

Supplementary Fig. 13

Supplementary Fig. 14

Supplementary Fig. 15

Supplementary Fig. 16

Supplementary Fig. 17

a

Top KEGG pathways
Endothelial upregulated genes (Knight-C4 vs Control)

b

Top KEGG pathways
Microglia downregulated genes (Knight-C4 vs Control)

Supplementary Fig. 18

Supplementary Fig. 19

a
Knight-C4 vs Knight-C1-3

b
Knight-C4 vs Control